1
|
Bonner ER, Dawood A, Gordish-Dressman H, Eze A, Bhattacharya S, Yadavilli S, Mueller S, Waszak SM, Nazarian J. Pan-cancer atlas of somatic core and linker histone mutations. NPJ Genom Med 2023; 8:23. [PMID: 37640703 PMCID: PMC10462747 DOI: 10.1038/s41525-023-00367-8] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2023] [Accepted: 08/07/2023] [Indexed: 08/31/2023] Open
Abstract
Recent genomic data points to a growing role for somatic mutations altering core histone and linker histone-encoding genes in cancer. However, the prevalence and the clinical and biological implications of histone gene mutations in malignant tumors remain incompletely defined. To address these knowledge gaps, we analyzed somatic mutations in 88 linker and core histone genes across 12,743 tumors from pediatric, adolescent and young adult (AYA), and adult cancer patients. We established a pan-cancer histone mutation atlas contextualized by patient age, survival outcome, and tumor location. Overall, 11% of tumors harbored somatic histone mutations, with the highest rates observed among chondrosarcoma (67%), pediatric high-grade glioma (pHGG, >60%), and lymphoma (>30%). Previously unreported histone mutations were discovered in pHGG and other pediatric brain tumors, extending the spectrum of histone gene alterations associated with these cancers. Histone mutation status predicted patient survival outcome in tumor entities including adrenocortical carcinoma. Recurrent pan-cancer histone mutation hotspots were defined and shown to converge on evolutionarily conserved and functional residues. Moreover, we studied histone gene mutations in 1700 pan-cancer cell lines to validate the prevalence and spectrum of histone mutations seen in primary tumors and derived histone-associated drug response profiles, revealing candidate drugs targeting histone mutant cancer cells. This study presents the first-of-its-kind atlas of both core and linker histone mutations across pediatric, AYA, and adult cancers, providing a framework by which specific cancers may be redefined in the context of histone and chromatin alterations.
Collapse
Affiliation(s)
- Erin R Bonner
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA
| | - Adam Dawood
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA
| | | | - Augustine Eze
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA
| | - Surajit Bhattacharya
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA
| | - Sabine Mueller
- Department of Neurology, Neurosurgery and Pediatrics, University of California San Francisco, San Francisco, CA, USA
- Department of Oncology, University Children's Hospital Zürich, Zürich, Switzerland
| | - Sebastian M Waszak
- Laboratory of Computational Neuro-Oncology, Swiss Institute for Experimental Cancer Research (ISREC), School of Life Sciences, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
- Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.
- Department of Neurology, University of California, San Francisco, San Francisco, CA, USA.
| | - Javad Nazarian
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.
- Department of Oncology, University Children's Hospital Zürich, Zürich, Switzerland.
| |
Collapse
|
2
|
Jackson ER, Duchatel RJ, Staudt DE, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara WSN, Grand ML, Kearney PS, Douglas AM, Findlay IJ, Germon ZP, McEwen HP, Beitaki TS, Patabendige A, Skerrett-Byrne DA, Nixon B, Smith ND, Day B, Manoharan N, Nagabushan S, Hansford JR, Govender D, McCowage GB, Firestein R, Howlett M, Endersby R, Gottardo NG, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, André N, Hulleman E, Eisenstat DD, Vitanza NA, Nazarian J, Koschmann C, Mueller S, Cain JE, Dun MD. ONC201 in combination with paxalisib for the treatment of H3K27-altered diffuse midline glioma. Cancer Res 2023; 83:CAN-23-0186. [PMID: 37145169 PMCID: PMC10345962 DOI: 10.1158/0008-5472.can-23-0186] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2023] [Revised: 04/26/2023] [Accepted: 05/03/2023] [Indexed: 05/06/2023]
Abstract
Diffuse midline gliomas (DMG), including diffuse intrinsic pontine gliomas (DIPGs), are the most lethal of childhood cancers. Palliative radiotherapy is the only established treatment, with median patient survival of 9-11 months. ONC201 is a DRD2 antagonist and ClpP agonist that has shown preclinical and emerging clinical efficacy in DMG. However, further work is needed to identify the mechanisms of response of DIPGs to ONC201 treatment and to determine whether recurring genomic features influence response. Using a systems-biological approach, we showed that ONC201 elicits potent agonism of the mitochondrial protease ClpP to drive proteolysis of electron transport chain and tricarboxylic acid cycle proteins. DIPGs harboring PIK3CA-mutations showed increased sensitivity to ONC201, while those harboring TP53-mutations were more resistant. Metabolic adaptation and reduced sensitivity to ONC201 was promoted by redox-activated PI3K/Akt signaling, which could be counteracted using the brain penetrant PI3K/Akt inhibitor, paxalisib. Together, these discoveries coupled with the powerful anti-DIPG/DMG pharmacokinetic and pharmacodynamic properties of ONC201 and paxalisib have provided the rationale for the ongoing DIPG/DMG phase II combination clinical trial NCT05009992.
Collapse
Affiliation(s)
- Evangeline R. Jackson
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Ryan J. Duchatel
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Dilana E. Staudt
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Mika L. Persson
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Abdul Mannan
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC
- Brain Tumor Institute, Children's National Hospital, Washington, DC
| | - Sarah Parackal
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia
| | - Shaye Game
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia
| | - Wai Chin Chong
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia
| | - W. Samantha N. Jayasekara
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia
| | - Marion Le Grand
- Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, Inserm, CNRS, Institut Paoli Calmettes, Marseille, France
| | - Padraic S. Kearney
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Alicia M. Douglas
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Izac J. Findlay
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Zacary P. Germon
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Holly P. McEwen
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Tyrone S. Beitaki
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Adjanie Patabendige
- Brain Barriers Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Department of Biology, Edge Hill University, Ormskirk, United Kingdom
| | - David A. Skerrett-Byrne
- School of Environmental and Life Sciences, College of Engineering, Science and Environment, University of Newcastle, Callaghan, New South Wales, Australia
- Infertility and Reproduction Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Brett Nixon
- School of Environmental and Life Sciences, College of Engineering, Science and Environment, University of Newcastle, Callaghan, New South Wales, Australia
- Infertility and Reproduction Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
| | - Nathan D. Smith
- Analytical and Biomolecular Research Facility Advanced Mass Spectrometry Unit, University of Newcastle, Callaghan, New South Wales, Australia
| | - Bryan Day
- QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia
| | - Neevika Manoharan
- Department of Paediatric Oncology, Sydney Children's Hospital, Randwick, New South Wales, Australia
| | - Sumanth Nagabushan
- Department of Paediatric Oncology, Sydney Children's Hospital, Randwick, New South Wales, Australia
| | - Jordan R. Hansford
- Michael Rice Cancer Centre, Women's and Children's Hospital, South Australia Health and Medical Research Institute, South Australia ImmunoGenomics Cancer Institute, University of Adelaide, Adelaide, Australia
| | - Dinisha Govender
- Department of Oncology, The Children's Hospital at Westmead, Westmead, New South Wales, Australia
| | - Geoff B. McCowage
- Department of Oncology, The Children's Hospital at Westmead, Westmead, New South Wales, Australia
| | - Ron Firestein
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia
| | - Meegan Howlett
- Brain Tumor Research Program, Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia
| | - Raelene Endersby
- Brain Tumor Research Program, Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia
| | - Nicholas G. Gottardo
- Brain Tumor Research Program, Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia
- Department of Pediatric and Adolescent Oncology and Hematology, Perth Children's Hospital, Perth, Australia
| | - Frank Alvaro
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
- John Hunter Children's Hospital, New Lambton Heights, New South Wales, Australia
| | - Sebastian M. Waszak
- Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway
- Department of Neurology, University of California, San Francisco, San Francisco, California
| | - Martin R. Larsen
- Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmark
| | - Yolanda Colino-Sanguino
- Cancer Epigenetics Biology and Therapeutics, Precision Medicine Theme, Children's Cancer Institute, Sydney, New South Wales, Australia
- School of Women's and Children's Health, University of NSW, Sydney, New South Wales, Australia
| | - Fatima Valdes-Mora
- Cancer Epigenetics Biology and Therapeutics, Precision Medicine Theme, Children's Cancer Institute, Sydney, New South Wales, Australia
- School of Women's and Children's Health, University of NSW, Sydney, New South Wales, Australia
| | - Andria Rakotomalala
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, Lille, France
- University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Samuel Meignan
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, Lille, France
- University of Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France
| | - Eddy Pasquier
- Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, Inserm, CNRS, Institut Paoli Calmettes, Marseille, France
- Metronomics Global Health Initiative, Marseille, France
| | - Nicolas André
- Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, Inserm, CNRS, Institut Paoli Calmettes, Marseille, France
- Metronomics Global Health Initiative, Marseille, France
- Department of Pediatric Oncology, La Timone Children's Hospital, AP-HM, Marseille, France
| | - Esther Hulleman
- Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands
| | - David D. Eisenstat
- Children's Cancer Centre, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia
- Neuro-Oncology Laboratory, Murdoch Children's Research Institute, Department of Paediatrics, University of Melbourne, Parkville, Victoria, Australia
| | - Nicholas A. Vitanza
- Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Seattle Children's Hospital, Seattle, Washington
| | - Javad Nazarian
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC
- Department of Pediatrics, University Children's Hospital Zurich, Zurich, Switzerland
- The George Washington University, School of Medicine and Health Sciences, Washington, DC
| | - Carl Koschmann
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan
| | - Sabine Mueller
- Department of Pediatrics, University Children's Hospital Zurich, Zurich, Switzerland
- Department of Neurology, Neurosurgery and Pediatric, University of California, San Francisco, California
| | - Jason E. Cain
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia
- Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia
| | - Matthew D. Dun
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, New South Wales, Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights, New South Wales, Australia
- Paediatric Program, Mark Hughes Foundation Centre for Brain Cancer Research, College of Health, Medicine, and Wellbeing, Callaghan, New South Wales, Australia
| |
Collapse
|
3
|
Jackson E, Duchatel R, Persson M, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara S, Le Grand M, Kearney P, Douglas A, Findlay I, Staudt D, Germon Z, Skerrett-Byrne D, Nixon B, Smith N, Hulleman E, Day B, McCowage G, Alvaro F, Waszak S, Larsen M, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Vitanza N, Nazarian J, Koschmann C, Cain J, Mueller S, Dun M. EXTH-12. PRECLINICAL AND CASE STUDY EXAMINATION OF THE COMBINATION OF THE CLPP AGONIST ONC201 WITH THE PI3K/AKT INHIBITOR PAXALISIB FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA. Neuro Oncol 2022. [PMCID: PMC9660771 DOI: 10.1093/neuonc/noac209.811] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Abstract
Diffuse midline gliomas (DMGs), including those of the pons (diffuse intrinsic pontine glioma - DIPG), are pediatric CNS tumors recognized as the most lethal of all children’s cancers. Palliative radiotherapy remains the only approved treatment, with survival just 9-11 months post-diagnosis. The brain-penetrant small molecule therapy, ONC201, shows preclinical and emerging efficacy in early-stage clinical trials. However, patients invariably develop resistance, with some patients and models completely refractory to treatment. Using a powerful combination of pharmacology, proteomics, genomics, epigenetics, in vitro and in vivo modeling, across ten international laboratories, we have uncovered mechanisms underpinning resistance to ONC201. We find ONC201 elicits antagonism of the Dopamine receptor D2 (DRD2), whilst also causing mitochondrial degradation through potent agonism of the mitochondrial protease CLPP. This drives proteolysis of the electron transport chain (ETC) proteins including Succinate dehydrogenase A (SDHA) and the critical mitochondrial tricarboxylic acid (TCA) cycle regulator, Isocitrate dehydrogenase 3B (IDH3B). Loss of TCA activity reduces α-ketoglutarate and inhibits lysine demethylation, increasing methylation of H3K4me3 and H3K27me3, thus, altering the epigenome of DIPG. Mitochondrial disruption elicited redox-activated RAS-PI3K/AKT signaling, counteracted using the PI3K/AKT inhibitor paxalisib. The combination of ONC201 and paxalisib synergistically extended survival of two aggressive DIPG PDX models (SU-DIPG-VI vehicle=73 vs. combination=100-days, p=0.0027; SF8626 vehicle=36 vs. combination=43-days, p=0.0002). Compassionate access to this combination (n=2 patients; immediately post-RT and following re-RT) resulted in dramatic reductions in tumor volume, extending overall survival for the patient at diagnosis and the patient at progression (e.g., MR axial diagnosis scan = 1554 mm2, following twelve months on the combination, current tumor volume = 464 mm2 (~70% reduction), patient remains in progression free survival, 15 months since diagnosis). The clinical utility of our preclinical data is currently under investigation in the PNOC022 clinical trial (NCT05009992).
Collapse
Affiliation(s)
- Evangeline Jackson
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - Ryan Duchatel
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - Mika Persson
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - Abdul Mannan
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children’s National Hospital , Washington, DC , USA
| | - Sarah Parackal
- Hudson Institute of Medical Research , Clayton, VIC , Australia
| | - Shaye Game
- Hudson Institute of Medical Research , Clayton, VIC , Australia
| | - Wai Chin Chong
- Hudson Institute of Medical Research , Clayton, VIC , Australia
| | | | - Marion Le Grand
- Laboratoire d’Oncologie Prédictive, CRCM, Institut Paoli-Calmettes, Aix-Marseille Université, Département d’Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France , Marseille , France
| | - Padraic Kearney
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - Alicia Douglas
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - Izac Findlay
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - Dilana Staudt
- 1 Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - Zacary Germon
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| | - David Skerrett-Byrne
- Infertility and Reproduction Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW , Australia
| | - Brett Nixon
- Infertility and Reproduction Research Program, Hunter Medical Research Institute, New Lambton Heights, NSW , Australia
| | - Nathan Smith
- Analytical and Biomolecular Research Facility Advanced Mass Spectrometry Unit, University of Newcastle , Callaghan, NSW , Australia
| | - Esther Hulleman
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands , Utrecht , Netherlands
| | - Bryan Day
- QIMR Berghofer Medical Research Institute , Herston, QLD , Australia
| | - Geoffrey McCowage
- Sydney Children's Hospitals Network , Westmead, New South Wales , Australia
| | - Frank Alvaro
- Precision Medicine Program, Hunter Medical Research Institute, New Lambton Heights, NSW , Australia
| | - Sebastian Waszak
- Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway , Oslo , Norway
| | - Martin Larsen
- Department of Biochemistry and Molecular Biology, University of Southern Denmark, Odense M, Denmark , Odense M , Denmark
| | - Yolanda Colino-Sanguino
- Cancer Epigenetics Biology and Therapeutics, Precision Medicine Theme, Children’s Cancer Institute , Sydney, NSW , Australia
| | - Fatima Valdes-Mora
- Cancer Epigenetics Biology and Therapeutics, Precision Medicine Theme, Children’s Cancer Institute , Sydney, NSW , Australia
| | - Andria Rakotomalala
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, F-59000 Lille, France, F-59000 Lille, France
| | - Samuel Meignan
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, F-59000 Lille, France , F-59000 Lille , France
| | - Eddy Pasquier
- Laboratoire d’Oncologie Prédictive, CRCM, Institut Paoli-Calmettes, Aix-Marseille Université, Département d’Oncologie Médicale, Institut Paoli-Calmettes, Marseille, France , Marseille , France
| | - Nicholas Vitanza
- Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute , Seattle, WA , USA
| | - Javad Nazarian
- Department of Oncology, Children’s Research Center, University Children’s Hospital Zurich, Zurich, Switzerland , Zurich , Switzerland
| | - Carl Koschmann
- Department of Pediatrics, Michigan Medicine , Ann Arbor, MI , USA
| | - Jason Cain
- Hudson Institute of Medical Research , Clayton, VIC , Australia
| | - Sabine Mueller
- UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco , San Francisco, CA , USA
| | - Matthew Dun
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
| |
Collapse
|
4
|
Kline C, Jain P, Kilburn L, Bonner ER, Gupta N, Crawford JR, Banerjee A, Packer RJ, Villanueva-Meyer J, Luks T, Zhang Y, Kambhampati M, Zhang J, Yadavilli S, Zhang B, Gaonkar KS, Rokita JL, Kraya A, Kuhn J, Liang W, Byron S, Berens M, Molinaro A, Prados M, Resnick A, Waszak SM, Nazarian J, Mueller S. Upfront Biology-Guided Therapy in Diffuse Intrinsic Pontine Glioma: Therapeutic, Molecular, and Biomarker Outcomes from PNOC003. Clin Cancer Res 2022; 28:3965-3978. [PMID: 35852795 PMCID: PMC9475246 DOI: 10.1158/1078-0432.ccr-22-0803] [Citation(s) in RCA: 20] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 05/22/2022] [Accepted: 07/15/2022] [Indexed: 01/07/2023]
Abstract
PURPOSE PNOC003 is a multicenter precision medicine trial for children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG). PATIENTS AND METHODS Patients (3-25 years) were enrolled on the basis of imaging consistent with DIPG. Biopsy tissue was collected for whole-exome and mRNA sequencing. After radiotherapy (RT), patients were assigned up to four FDA-approved drugs based on molecular tumor board recommendations. H3K27M-mutant circulating tumor DNA (ctDNA) was longitudinally measured. Tumor tissue and matched primary cell lines were characterized using whole-genome sequencing and DNA methylation profiling. When applicable, results were verified in an independent cohort from the Children's Brain Tumor Network (CBTN). RESULTS Of 38 patients enrolled, 28 patients (median 6 years, 10 females) were reviewed by the molecular tumor board. Of those, 19 followed treatment recommendations. Median overall survival (OS) was 13.1 months [95% confidence interval (CI), 11.2-18.4] with no difference between patients who followed recommendations and those who did not. H3K27M-mutant ctDNA was detected at baseline in 60% of cases tested and associated with response to RT and survival. Eleven cell lines were established, showing 100% fidelity of key somatic driver gene alterations in the primary tumor. In H3K27-altered DIPGs, TP53 mutations were associated with worse OS (TP53mut 11.1 mo; 95% CI, 8.7-14; TP53wt 13.3 mo; 95% CI, 11.8-NA; P = 3.4e-2), genome instability (P = 3.1e-3), and RT resistance (P = 6.4e-4). The CBTN cohort confirmed an association between TP53 mutation status, genome instability, and clinical outcome. CONCLUSIONS Upfront treatment-naïve biopsy provides insight into clinically relevant molecular alterations and prognostic biomarkers for H3K27-altered DIPGs.
Collapse
Affiliation(s)
- Cassie Kline
- Division of Oncology, Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
| | - Payal Jain
- Division of Neurosurgery, Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Lindsay Kilburn
- Department of Hematology and Oncology, Children's National Hospital, Washington, DC
| | - Erin R. Bonner
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC.,Institute for Biomedical Sciences, The George Washington University School of Medicine and Health Sciences, Washington, DC
| | - Nalin Gupta
- Department of Neurological Surgery, University of California, San Francisco, California
| | - John R. Crawford
- Department of Neuroscience, University of California, San Diego, California.,Rady Children's Hospital San Diego, San Diego, California
| | - Anu Banerjee
- Department of Neurological Surgery, University of California, San Francisco, California.,Department of Pediatrics, University of California, San Francisco, California
| | - Roger J. Packer
- Center for Neuroscience and Behavioral Medicine, Children's National Hospital, Washington, DC
| | - Javier Villanueva-Meyer
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California
| | - Tracy Luks
- Department of Radiology and Biomedical Imaging, University of California, San Francisco, California
| | - Yalan Zhang
- Department of Neurological Surgery, University of California, San Francisco, California.,Department of Epidemiology and Biostatistics, University of California, San Francisco, California
| | - Madhuri Kambhampati
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC
| | - Jie Zhang
- Department of Neurology, University of California, San Francisco, California
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC
| | - Bo Zhang
- Division of Neurosurgery, Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Krutika S. Gaonkar
- Division of Neurosurgery, Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.,Department of Bioinformatics and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Jo Lynne Rokita
- Division of Neurosurgery, Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania.,Department of Bioinformatics and Health Informatics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Adam Kraya
- Division of Neurosurgery, Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - John Kuhn
- College of Pharmacy, University of Texas Health Science Center, San Antonio, Texas
| | - Winnie Liang
- Translational Genomic Research Institute (TGEN), Phoenix, Arizona
| | - Sara Byron
- Translational Genomic Research Institute (TGEN), Phoenix, Arizona
| | - Michael Berens
- Translational Genomic Research Institute (TGEN), Phoenix, Arizona
| | - Annette Molinaro
- Department of Neurological Surgery, University of California, San Francisco, California.,Department of Epidemiology and Biostatistics, University of California, San Francisco, California
| | - Michael Prados
- Department of Neurological Surgery, University of California, San Francisco, California
| | - Adam Resnick
- Division of Neurosurgery, Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Sebastian M. Waszak
- Department of Neurology, University of California, San Francisco, California.,Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway.,Division of Pediatric and Adolescent Medicine, Department of Pediatric Research, Rikshospitalet, Oslo University Hospital, Oslo, Norway
| | - Javad Nazarian
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC.,Institute for Biomedical Sciences, The George Washington University School of Medicine and Health Sciences, Washington, DC.,Department of Oncology, University Children's Hospital Zürich, Zürich, Switzerland
| | - Sabine Mueller
- Department of Neurological Surgery, University of California, San Francisco, California.,Department of Pediatrics, University of California, San Francisco, California.,Department of Neurology, University of California, San Francisco, California.,Department of Oncology, University Children's Hospital Zürich, Zürich, Switzerland.,Corresponding Author: Sabine Mueller, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143. Phone: 415-502-7301; Fax: 415-502-7299; E-mail:
| |
Collapse
|
5
|
Przystal JM, Cianciolo Cosentino C, Yadavilli S, Zhang J, Laternser S, Bonner ER, Prasad R, Dawood AA, Lobeto N, Chin Chong W, Biery MC, Myers C, Olson JM, Panditharatna E, Kritzer B, Mourabit S, Vitanza NA, Filbin MG, de Iuliis GN, Dun MD, Koschmann C, Cain JE, Grotzer MA, Waszak SM, Mueller S, Nazarian J. Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. Neuro Oncol 2022; 24:1438-1451. [PMID: 35157764 PMCID: PMC9435508 DOI: 10.1093/neuonc/noac041] [Citation(s) in RCA: 28] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Pediatric diffuse midline gliomas (DMGs) are incurable childhood cancers. The imipridone ONC201 has shown early clinical efficacy in a subset of DMGs. However, the anticancer mechanisms of ONC201 and its derivative ONC206 have not been fully described in DMGs. METHODS DMG models including primary human in vitro (n = 18) and in vivo (murine and zebrafish) models, and patient (n = 20) frozen and FFPE specimens were used. Drug-target engagement was evaluated using in silico ChemPLP and in vitro thermal shift assay. Drug toxicity and neurotoxicity were assessed in zebrafish models. Seahorse XF Cell Mito Stress Test, MitoSOX and TMRM assays, and electron microscopy imaging were used to assess metabolic signatures. Cell lineage differentiation and drug-altered pathways were defined using bulk and single-cell RNA-seq. RESULTS ONC201 and ONC206 reduce viability of DMG cells in nM concentrations and extend survival of DMG PDX models (ONC201: 117 days, P = .01; ONC206: 113 days, P = .001). ONC206 is 10X more potent than ONC201 in vitro and combination treatment was the most efficacious at prolonging survival in vivo (125 days, P = .02). Thermal shift assay confirmed that both drugs bind to ClpP, with ONC206 exhibiting a higher binding affinity as assessed by in silico ChemPLP. ClpP activation by both drugs results in impaired tumor cell metabolism, mitochondrial damage, ROS production, activation of integrative stress response (ISR), and apoptosis in vitro and in vivo. Strikingly, imipridone treatment triggered a lineage shift from a proliferative, oligodendrocyte precursor-like state to a mature, astrocyte-like state. CONCLUSION Targeting mitochondrial metabolism and ISR activation effectively impairs DMG tumorigenicity. These results supported the initiation of two pediatric clinical trials (NCT05009992, NCT04732065).
Collapse
Affiliation(s)
- Justyna M Przystal
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
| | - Chiara Cianciolo Cosentino
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
| | - Sridevi Yadavilli
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
- Research Center for Genetic Medicine, Children’s National Hospital, Washington, DC, USA
| | - Jie Zhang
- Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - Sandra Laternser
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
| | - Erin R Bonner
- Research Center for Genetic Medicine, Children’s National Hospital, Washington, DC, USA
| | - Rachna Prasad
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
| | - Adam A Dawood
- Research Center for Genetic Medicine, Children’s National Hospital, Washington, DC, USA
| | - Nina Lobeto
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
| | - Wai Chin Chong
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia and Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia
| | - Matt C Biery
- The Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - Carrie Myers
- The Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, Seattle, Washington, USA
| | - James M Olson
- Fred Hutchinson Cancer Research Center, Seattle, Washington, USA
| | - Eshini Panditharatna
- Department of Pediatric Oncology, Dana-Farber Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, USA
| | - Bettina Kritzer
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
| | - Sulayman Mourabit
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
| | - Nicholas A Vitanza
- The Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute, Seattle, Washington, USA
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle, Washington, USA
| | - Mariella G Filbin
- Department of Pediatric Oncology, Dana-Farber Boston Children’s Cancer and Blood Disorders Center, Boston, Massachusetts, USA
| | - Geoffry N de Iuliis
- Reproductive Science Group, College of Engineering, Science and Environment, University of Newcastle, Callaghan, New South Wales, Australia
| | - Matthew D Dun
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, Hunter Medical Research Institute, University of Newcastle, Callaghan, New South Wales, Australia
| | - Carl Koschmann
- Department of Pediatrics, Michigan Medicine, Ann Arbor, Michigan, USA
| | - Jason E Cain
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Victoria, Australia and Department of Molecular and Translational Science, Monash University, Clayton, Victoria, Australia
| | - Michael A Grotzer
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
| | - Sebastian M Waszak
- Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Oslo, Norway
| | - Sabine Mueller
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
- Department of Pediatrics and Neurosurgery, University of California, San Francisco, San Francisco, California, USA
- Department of Neurology, University of California, San Francisco, San Francisco, California, USA
| | - Javad Nazarian
- Department of Oncology, Children’s Research Center, University Children’s HospitalZurich, Zurich, Switzerland
- Research Center for Genetic Medicine, Children’s National Hospital, Washington, DC, USA
| |
Collapse
|
6
|
Dun MD, Jackson ER, Duchatel RJ, Persson ML, Mannan A, Yadavilli S, Parackal S, Game S, Chong WC, Jayasekara S, Le Grand M, Kearney PS, Douglas AM, Findlay IJ, Staudt D, Germon ZP, Skerrett-Byrne DA, Nixon B, Smith ND, Hulleman E, Day B, McCowage GB, Alvaro F, Waszak SM, Larsen MR, Colino-Sanguino Y, Valdes-Mora F, Rakotomalala A, Meignan S, Pasquier E, Vitanza NA, Nazarian J, Koschmann C, Cain J, Mueller S. DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992). Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac079.064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Diffuse midline gliomas (DMG), including those of the brainstem (diffuse intrinsic pontine glioma - DIPG), are pediatric CNS tumors recognized as the most lethal of all children’s cancers. Palliative radiotherapy is the only approved treatment, with survival just 9-11–months post-diagnosis. ONC201 shows preclinical and emerging clinical efficacy in early-stage clinical trials, extending survival of DIPG patients by ~9-11–months compared to historic controls. However, patients invariably develop resistance, with some patients completely refractory to treatment. Using a multi-omics approach, including pharmacology, proteomics, genomics, epigenetics, in vitro and in vivo modeling, across ten international laboratories, we have uncovered the inherent mechanisms of resistance to ONC201. We find ONC201 elicits antagonism of the Dopamine receptor D2 (DRD2), whilst also causing mitochondrial degradation through potent agonism of the Mitochondrial protease CLPP, that drives proteolysis of the electron transport chain (ETC) protein Succinate dehydrogenase A (SDHA) and degradation of critical mitochondrial tricarboxylic acid (TCA) cycle regulator Isocitrate dehydrogenase 3B (IDH3B). Loss mitochondrial respiration increased hypoxia and reduced α-ketoglutarate, inhibiting lysine demethylation, increasing methylation of H3K4me3 and H3K27me3, thus altering the epigenome of primary DIPG cells. Loss of SDHA caused oxidation of succinate forming superoxide driving redox regulated PI3K/AKT signaling, counteracted using the PI3K/AKT inhibitor paxalisib. The combination of ONC201 and paxalisib synergically extended survival of two aggressive DIPG PDX models (SU-SIPG-VI vehicle=73 vs. combination=100-days, p=0.0027; SF8626 vehicle=36 vs. combination=43-days, p=0.0002). Compassionate access to this combination (n=2 patients; immediately post-RT and following re-RT) resulted in reductions in tumor volume and complete resolution of disease symptoms, extending overall survival (e.g., diagnosis patient MR axial scan=1554 mm2 , following eight months on the combination, current tumor volume=464 mm2 (<70%), patient remains on treatment). Our findings harness the powerful anti-DMG/DIPG pharmacokinetic/dynamic properties of ONC201 and paxalisib, a combination that is currently in clinical trials (NCT05009992).
Collapse
Affiliation(s)
- Matthew D Dun
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Evangeline R Jackson
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Ryan J Duchatel
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Mika L Persson
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Abdul Mannan
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children’s National Hospital , Washington, DC , USA
- Brain Tumor Institute, Children’s National Hospital , Washington, DC , USA
| | - Sarah Parackal
- Hudson Institute of Medical Research , Clayton, VIC , Australia
- Department of Molecular and Translational Science, Monash University , Clayton, VIC , Australia
| | - Shaye Game
- Hudson Institute of Medical Research , Clayton, VIC , Australia
- Department of Molecular and Translational Science, Monash University , Clayton, VIC , Australia
| | - Wai Chin Chong
- Hudson Institute of Medical Research , Clayton, VIC , Australia
- Department of Molecular and Translational Science, Monash University , Clayton, VIC , Australia
| | - Samantha Jayasekara
- Hudson Institute of Medical Research , Clayton, VIC , Australia
- Department of Molecular and Translational Science, Monash University , Clayton, VIC , Australia
| | - Marion Le Grand
- Laboratoire d’Oncologie Prédictive, CRCM, Institut Paoli-Calmettes, Aix-Marseille Université, Département d’Oncologie Médicale, Institut Paoli-Calmettes , Marseille , France
- Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, Inserm, CNRS, Institut Paoli Calmettes , Marseille , France
| | - Padraic S Kearney
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Alicia M Douglas
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Izac J Findlay
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Dilana Staudt
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - Zacary P Germon
- Cancer Signalling Research Group, School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle , Callaghan, NSW , Australia
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
| | - David A Skerrett-Byrne
- Priority Research Centre for Reproductive Science, School of Environmental and Life Sciences, The University of Newcastle , Callaghan, NSW , Australia
| | - Brett Nixon
- Priority Research Centre for Reproductive Science, School of Environmental and Life Sciences, The University of Newcastle , Callaghan, NSW , Australia
| | - Nathan D Smith
- Analytical and Biomolecular Research Facility Advanced Mass Spectrometry Unit, University of Newcastle , Callaghan, NSW , Australia
| | - Esther Hulleman
- Princess Máxima Center for Pediatric Oncology , Utrecht , Netherlands
| | - Bryan Day
- QIMR Berghofer Medical Research Institute , Herston, QLD , Australia
| | - Geoff B McCowage
- Department of Oncology, The Children's Hospital at Westmead , Westmead, NSW , Australia
| | - Frank Alvaro
- Precision Medicine Research Program, Hunter Medical Research Institute, New Lambton Heights , NSW , Australia
- John Hunter Children’s Hospital, New Lambton Heights , NSW , Australia
| | - Sebastian M Waszak
- Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital , Oslo , Norway
- Department of Neurology, University of California, San Francisco , CA , USA
| | - Martin R Larsen
- Department of Biochemistry and Molecular Biology, University of Southern Denmark , Odense M , Denmark
| | - Yolanda Colino-Sanguino
- Cancer Epigenetics Biology and Therapeutics, Precision Medicine Theme, Children’s Cancer Institute , Sydney, NSW , Australia
- School of Children and Women Health, University of NSW , Sydney, NSW , Australia
| | - Fatima Valdes-Mora
- Cancer Epigenetics Biology and Therapeutics, Precision Medicine Theme, Children’s Cancer Institute , Sydney, NSW , Australia
- School of Children and Women Health, University of NSW , Sydney, NSW , Australia
| | - Andria Rakotomalala
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, F-
- Lille, France, Univ. Lille, CNRS, Inserm, CHU Lille, UMR-U- CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France
| | - Samuel Meignan
- Tumorigenesis and Resistance to Treatment Unit, Centre Oscar Lambret, F-
- Lille, France, Univ. Lille, CNRS, Inserm, CHU Lille, UMR-U- CANTHER – Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France
| | - Eddy Pasquier
- Centre de Recherche en Cancérologie de Marseille, Aix-Marseille Université, Inserm, CNRS, Institut Paoli Calmettes , Marseille , France
- Metronomics Global Health Initiative , Marseille , France
| | - Nicholas A Vitanza
- Ben Towne Center for Childhood Cancer Research, Seattle Children’s Research Institute , Seattle, WA , USA
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, Seattle Children’s Hospital , Seattle, WA , USA
| | - Javad Nazarian
- Department of Oncology, Children’s Research Center, University Children’s Hospital Zürich , Zurich , Switzerland
- The George Washington University, School of Medicine and Health Sciences , Washington, DC , USA
| | - Carl Koschmann
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Michigan, Ann Arbor , MI , USA
| | - Jason Cain
- Hudson Institute of Medical Research , Clayton, VIC , Australia
- Department of Molecular and Translational Science, Monash University , Clayton, VIC , Australia
| | - Sabine Mueller
- Department of Oncology, Children’s Research Center, University Children’s Hospital Zürich , Zurich , Switzerland
- Pediatric Hematology-Oncology and Neurology, UCSF Benioff Children’s Hospital , CA , USA
| |
Collapse
|
7
|
Putnam E, Yadavilli S, Dawood A, Mizoguchi S, Subramaniam B, Bornhorst M, Nazarian J. NFB-20. Pre-clinical models of Mismatch Repair Deficient Gliomas. Neuro Oncol 2022. [PMCID: PMC9165132 DOI: 10.1093/neuonc/noac079.480] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
INTRODUCTION: Lynch syndrome and Biallelic Mismatch Repair Deficiency (BMMRD) are hereditary tumor predisposition syndromes, resulting from one or two (respectively) germline alterations in DNA mis-match repair (MMR) genes. Currently, there are few treatments for mismatch repair deficient (MMRD) gliomas, in part due to a lack of suitable pre-clinical models for drug testing. The purpose of this study is to develop and characterize pre-clinical models of MMRD gliomas. METHODS: Primary cells were developed from patients diagnosed with MMRD gliomas and characterized through immunofluorescence staining (IF) for different cell type markers, western blot assays, and genome and transcriptome analysis. Murine models were generated through intracranial injection of mCherry-luciferase reporter expressing primary cells, and mice were monitored for evidence of engraftment and clinical symptoms. Drug screening on the cell lines was performed to identify potential therapeutic agents for in-vivo testing. RESULTS: The cell lines had similar characteristics as the primary glial tumors by IF staining and genome and transcriptome analysis. Adult NSG mice developed tumors around three weeks after intercranial transplantation of the tumor cells. These tumors closely resembled the primary patient tumors on histology. Preliminary drug testing on the cell lines showed efficacy of ONC201, ONC206, and RM006 against MMRD gliomas with IC50 concentrations of 1.77 μM, 185 nM, and 699 nM respectively. CONCLUSION: The generation of pre-clinical MMRD glioma models can lead to improved understanding of tumorigenesis, allowing for the identification of targetable molecules, and supporting novel treatment development.
Collapse
Affiliation(s)
- Ethan Putnam
- Children's National Hospital , Washington, DC , USA
| | | | - Adam Dawood
- Children's National Hospital , Washington, DC , USA
| | | | | | - Miriam Bornhorst
- Children's National Hospital , Washington, DC , USA
- George Washington University , Washington, DC , USA
| | - Javad Nazarian
- University Children's Hospital Zurich , Zurich , Switzerland
- Children's National Hospital , Washington, DC , USA
| |
Collapse
|
8
|
Kline C, Jain P, Kilburn L, Bonner E, Gupta N, Crawford J, Banerjee A, Packer R, Villanueva-Meyer J, Luks T, Zhang Y, Kambhampati M, Zhang J, Yadavilli S, Kraya A, Kuhn J, Liang W, Byron S, Berens M, Molinaro A, Prados M, Resnick A, Waszak S, Nazarian J, Mueller S. DIPG-31. Prognostic and predictive biomarkers of response in children and young adults with H3K27M-altered diffuse intrinsic pontine glioma: results from a multi-center, interventional clinical trial (PNOC003). Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac079.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
BACKGROUND: Diffuse intrinsic pontine glioma (DIPG) is a fatal brain tumor. Herein, we report on novel prognostic and predictive genomic biomarkers identified in PNOC003, a multi-center precision medicine trial for children and young adults diagnosed with DIPG. METHODS: Patients aged 3-25 years were enrolled on PNOC003 based on radiographic diagnosis of DIPG. Pre-treatment tumor biopsies were analyzed using tumor-normal whole-exome sequencing and mRNA-tumor sequencing to determine biology-informed, multi-agent therapy following radiation therapy (RT). Whole-genome sequencing was performed as an exploratory study aim. Genomic biomarkers were investigated to identify predictors of RT response and overall survival (OS) in patients with confirmed H3K27M-altered DIPG. Prognostic biomarkers were verified in a retrospective, H3K27M-altered diffuse midline glioma cohort (n=22) from the Children’s Brain Tumor Network (CBTN). RESULTS: Thirty patients enrolled on PNOC003 met molecular criteria for H3K27M-altered DIPG. TP53 was the most frequently altered driver gene (73%). Somatic alterations in PTEN>TP53>PDGFRA were independently associated with OS (P<0.05, in order of negative impact on survival). TP53 mutations associated with worse OS (TP53mut 11.1 mo [95% CI 8.7, 14]; TP53wt 13.3 mo [95% CI 11.8, NA]; P=3e-2), chromosomal instability (P=3e-3), and resistance to RT (P=6e-4). Moreover, loss of chromosome 10q, encoding tumor suppressor PTEN, was associated with worse OS, co-occurred with PTEN alterations, biallelic PTEN inactivation and loss of gene expression. The combination of TP53 alterations and loss of 10q/PTEN in H3K27M-altered DIPG was associated with the worst OS in a combined PNOC003 and CBTN cohort (TP53mut/10qdel, n=14, OS 8.4 mo [95% CI 7.4, 15.8]; TP53mut/10qwt, n=20, OS 13.1 mo [95% CI 10.1, 17.2]; TP53wt/10qwt, n=14, OS 15.5 mo [11.8, 29.4]; P=2e-3). CONCLUSION: PNOC003, a tissue-driven clinical trial, provided insights into prognostic and predictive genomic biomarkers and informed a novel molecular tumor classification system for H3K27M-altered DIPGs.
Collapse
Affiliation(s)
- Cassie Kline
- Children's Hospital of Philadelphia , Philadelphia, PA , USA
| | - Payal Jain
- Children's Hospital of Philadelphia , Philadelphia, PA , USA
| | | | - Erin Bonner
- Children’s National Hospital, Washington , DC, DC , USA
- The George Washington University School of Medicine and Health Sciences, Washington , DC, DC , USA
| | - Nalin Gupta
- University of California, San Francisco, San Francisco , CA , USA
| | - John Crawford
- University of California, San Diego, San Diego , CA , USA
| | - Anu Banerjee
- University of California, San Francisco, San Francisco , CA , USA
| | - Roger Packer
- Children’s National Hospital, Washington , DC, DC , USA
| | | | - Tracy Luks
- University of California, San Francisco, San Francisco , CA , USA
| | - Yalan Zhang
- University of California, San Francisco, San Francisco , CA , USA
| | | | - Jie Zhang
- University of California, San Francisco, San Francisco , CA , USA
| | | | - Adam Kraya
- Children's Hospital of Philadelphia , Philadelphia, PA , USA
| | - John Kuhn
- University of Texas Health Science Center , Austin, TX , USA
| | - Winnie Liang
- Translational Genomic Research Institute , Phoenix, AZ , USA
| | - Sara Byron
- Translational Genomic Research Institute , Phoenix, AZ , USA
| | - Michael Berens
- Translational Genomic Research Institute , Phoenix, AZ , USA
| | - Annette Molinaro
- University of California, San Francisco, San Francisco , CA , USA
| | - Michael Prados
- University of California, San Francisco, San Francisco , CA , USA
| | - Adam Resnick
- Children's Hospital of Philadelphia , Philadelphia, PA , USA
| | | | - Javad Nazarian
- Children’s National Hospital, Washington , DC, DC , USA
- University Children's Hospital Zürich , Zurich , Switzerland
| | - Sabine Mueller
- University of California, San Francisco, San Francisco , CA , USA
- University Children's Hospital Zürich , Zurich , Switzerland
| |
Collapse
|
9
|
Przystal JM, Cosentino CC, Yadavilli S, Zhang J, Laternser S, Bonner ER, Biery M, Vitanza NA, Koschmann C, Cain J, Waszak SM, Mueller S, Nazarian J. HGG-32. ONC201 AND ONC206 TARGET TUMOR CELL METABOLISM IN PEDIATRIC DIFFUSE MIDLINE GLIOMA PRECLINICAL MODELS. Neuro Oncol 2021. [DOI: 10.1093/neuonc/noab090.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Diffuse midline gliomas (DMGs) remain incurable cancers and new treatments are urgently needed. One promising new therapeutic avenue for these cancers is targeting of metabolic vulnerabilities including a heightened dependence on mitochondrial metabolism. We and others have shown that the oral, brain-penetrant imipridone drugs ONC201 and ONC206 target mitochondrial metabolism in cancer cells. In particular, ONC201 and ONC206 hyper-activate the mitochondrial protease ClpP, impair mitochondrial oxidative phosphorylation (OXPHOS), activate the integrated stress response (ISR) signaling pathway, and induce apoptosis in DMG preclinical models. We validated ClpP as a key target of ONC206 by showing that CRISPR/Cas9-mediated CLPP knockout significantly decreased ONC206 sensitivity in DMG cells. We further showed that imipridone-mediated ClpP activation resulted in significant degradation of the chaperone protein ClpX. Moreover, ONC201 and ONC206 treatment inhibited mitochondrial respiration, decreased mitochondrial membrane potential and triggered extensive mitochondrial structural damage, including disintegration of mitochondrial cristae. Time-course RNA sequencing of five DMG cell lines treated with ONC201 and ONC206, alone or in combination, revealed robust ATF4 and CHOP upregulation, indicating potent activation of ISR signaling. Notably, ATF4/CHOP upregulation was strongest in ONC201/6 combination-treated cells, indicating synergy between the two drugs. We further explored drug combinations by testing ONC201 together with ONC206, Panobinostat, JQ1, and Osimertinib to identify synergistic combination treatments. The strongest synergistic effect was found over a broad IC50 range for ONC201 and ONC206. Finally, we showed that ONC201 and ONC206 significantly prolonged survival of mice bearing brainstem DIPG xenografts. Ongoing studies include assessment of the in vivo efficacy of ONC201 and ONC206 across different CNS tumor models, as well as investigation and validation of clinically relevant biomarkers of response to treatment. In summary, our preclinical data strongly support the utility of the mitochondrial targeting agents ONC201 and ONC206 for the treatment of DMG and other malignant brain tumors.
Collapse
Affiliation(s)
- Justyna M Przystal
- Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | | | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children’s National Medical Center, Washington, DC, USA
| | - Jie Zhang
- UCSF Department of Neurology, Neurosurgery and Pediatrics, San Francisco, CA, USA
| | - Sandra Laternser
- Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Erin R Bonner
- Center for Genetic Medicine Research, Children’s National Medical Center, Washington, DC, USA
| | - Matt Biery
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Nicholas A Vitanza
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle Children’s Hospital, Seattle, WA, USA
| | - Carl Koschmann
- Department of Pediatrics, Michigan Medicine, Ann Arbor, MI, USA
| | - Jason Cain
- Developmental and Cancer Biology Centre for Cancer Research Hudson Institute of Medical Research, Melbourne, Australia
| | - Sebastian M Waszak
- Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo, Oslo, Norway
| | - Sabine Mueller
- UCSF Department of Neurology, Neurosurgery and Pediatrics, San Francisco, CA, USA
- Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Javad Nazarian
- Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
- Center for Genetic Medicine Research, Children’s National Medical Center, Washington, DC, USA
| |
Collapse
|
10
|
Cosentino CC, Laternser S, Przystal JM, Yadavilli S, Zhang J, Müller T, Kritzer B, Müller S, Nazarian J. HGG-23. IN VITRO AND IN VIVO PRECLINICAL DRUG SCREENING OF PROMISING THERAPEUTICS FOR DIFFUSE MIDLINE GLIOMA (DMG). Neuro Oncol 2021. [PMCID: PMC8263150 DOI: 10.1093/neuonc/noab090.087] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Introduction Diffuse midline gliomas (DMGs) are amongst the most unforgiving pediatric brain tumors, characterized by an intrinsic resistance to therapy. Despite major advances in understanding of tumor biology, the prognosis remains exceedingly poor, and treatment options are limited. New therapeutics are being evaluated at a fast rate by different laboratories. In order to prioritize effective drug candidates for DMG treatment, we comprehensively characterized a panel of promising therapeutic agents in in vitro and in different vivo systems. Methods We determined the sensitivity of primary DMG cell lines to a panel of small molecule inhibitors targeting known DMG targets and pathways. Dose response curves were generated for more than 20 different compounds and possible synergistic effects were investigated by SynergieFinder. In an effort to highlight potential toxicities and associated mechanisms at a large scale, we performed a preclinical toxicity evaluation in zebrafish larvae, with a slightly modified version of the official Fish Embryo Acute Toxicity (FET) test. Drug toxicity was tested by continuous exposure of zebrafish larvae to increasing concentrations of the different compounds. Survival curves, morphological analyses and behavioral tests were performed at a maximum tolerated dose (MTD). To confirm the findings obtained in zebrafish, we further performed in vivo studies in mice for promising candidates. Results Among the tested drugs in vitro we found 10 drugs showing promising dose- dependent reduction in cell viability with IC50 in nM to µM range. These were further evaluated for toxicity in zebrafish. The zebrafish larvae toxicities observations strongly correlated with the findings in murine in vivo studies, reinforcing the importance of zebrafish as an accurate investigative toxicology model to assess acute toxicity of molecules in preclinical studies. Conclusions By testing a wide range of drugs, targeting different pathways on DMG cells and in different in vivo systems we identified promising drug candidates for clinical management of children diagnosed with DMG.
Collapse
Affiliation(s)
| | | | | | | | - Jie Zhang
- UCSF Department of Neurology, San Francisco, CA, USA
| | - Timothy Müller
- University Children’s Hospital Zurich, Zurich, Switzerland
| | | | - Sabine Müller
- UCSF Department of Neurology, San Francisco, CA, USA
- University Children’s Hospital Zurich, Zurich, Switzerland
| | - Javad Nazarian
- University Children’s Hospital Zurich, Zurich, Switzerland
- Children’s National Medical Center, Washington DC, USA
| |
Collapse
|
11
|
Bonner E, Gaonkar K, Jain P, Zhu Y, Laternser S, Eze A, Kambhampati M, Yadavilli S, Cain J, Mueller S, Waszak S, Nazarian J. OMIC-09. MAPPING THE HISTONE MUTATIONAL LANDSCAPE ACROSS ADULT AND PEDIATRIC CANCER GENOMES UNCOVERS NOVEL SOMATIC MUTATIONS IN PEDIATRIC HIGH-GRADE GLIOMAS. Neuro Oncol 2021. [PMCID: PMC8168168 DOI: 10.1093/neuonc/noab090.156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
There is a growing role for mutations affecting histone linker and histone core-encoding genes across several adult and pediatric cancers. However, the extent to which somatic histone mutations may bridge across different cancers as common tumorigenic events – particularly in the context of pediatric CNS tumors – remains unclear. To address this knowledge gap, we set out to define a comprehensive pan-cancer landscape of somatic histone mutations. We first queried the ICGC PCAWG and TCGA Pan-Cancer Atlas representing >12,500 adult and pediatric cancer patients. We found lymphomas to be most enriched for histone mutations (50–75%) and, in particular, for mutations in linker histones (HIST1H1B-E), yet also in specific core histone genes (eg, HIST2H2BE). Moreover, we observed a significant enrichment of histone mutations in adult high-grade vs low-grade gliomas (10% vs 6%, P<0.05, n=922 patients). Interrogation of whole genome data from 800 pediatric CNS tumor genomes (PBTA/OpenDIPG), identified novel (non-H3K27/non-H3G34) somatic histone mutations in 5–10% of subjects, including pediatric high-grade gliomas (pHGGs) and diffuse midline gliomas (DMGs). We found an overlapping set of histone genes to be recurrently mutated in non-CNS cancers and pediatric CNS tumors alike (eg, HIST1H1B/C/E). Notably, the only pediatric primary CNS lymphoma patient also harbored a histone linker alteration (HIST1H1B), similar to adult non-CNS lymphoma patients. We validated novel somatic histone mutations in DMGs by Sanger sequencing. Ongoing studies include in vitro assessment of the impact of these mutations on cell proliferation, chromatin accessibility, histone spacing, and gene expression. In addition, we will further assess associations with clinical outcome, age, and tumor subtypes. Collectively, oncohistone vulnerabilities were identified and defined as histone gene families recurrently mutated across all cancer types. Our analyses of adult and pediatric cancer genomes have uncovered previously unknown mutations affecting histone linker and core proteins, which may play a yet-undefined role in tumor etiology.
Collapse
Affiliation(s)
- Erin Bonner
- Children’s National Medical Center, Center for Genetic Medicine Research, Washington, DC, USA
- The George Washington University, Institute for Biomedical Sciences, Washington, DC, USA
| | - Krutika Gaonkar
- Children’s Hospital of Philadelphia, Center for Data Driven Discovery in Biomedicine, Philadelphia, PA, USA
| | - Payal Jain
- Children’s Hospital of Philadelphia, Center for Data Driven Discovery in Biomedicine, Philadelphia, PA, USA
| | - Yuankun Zhu
- Children’s Hospital of Philadelphia, Center for Data Driven Discovery in Biomedicine, Philadelphia, PA, USA
| | - Sandra Laternser
- University Children’s Hospital Zürich, Department of Oncology, Zurich, Switzerland
| | - Augustine Eze
- Children’s National Medical Center, Center for Genetic Medicine Research, Washington, DC, USA
| | - Madhuri Kambhampati
- Children’s National Medical Center, Center for Genetic Medicine Research, Washington, DC, USA
| | - Sridevi Yadavilli
- Children’s National Medical Center, Center for Genetic Medicine Research, Washington, DC, USA
| | - Jason Cain
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Australia
| | - Sabine Mueller
- University Children’s Hospital Zürich, Department of Oncology, Zurich, Switzerland
- University of San Francisco California, Department of Neurology, Neurosurgery and Pediatrics, San Francisco, CA, USA
| | - Sebastian Waszak
- Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway
- Department of Pediatric Research, Division of Paediatric and Adolescent Medicine, Rikshospitalet, Oslo University Hospital, Oslo, Norway
| | - Javad Nazarian
- University Children’s Hospital Zürich, Department of Oncology, Zurich, Switzerland
- Children’s National Medical Center, Center for Genetic Medicine Research, Washington, DC, USA
| |
Collapse
|
12
|
Mueller T, Yadavilli S, Laternser S, Cianciolo C, Przystal J, Bonner E, Biery MC, Vitanza NA, Grotzer M, Mueller S, Nazarian J. HGG-24. PRECLINICAL EFFICACY OF THE BRAIN PENETRANT CYCLIN-DEPENDENT KINASE INHIBITOR ZOTIRACICLIB IN PEDIATRIC DIFFUSE MIDLINE GLIOMAS. Neuro Oncol 2021. [PMCID: PMC8168210 DOI: 10.1093/neuonc/noab090.088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Children diagnosed with diffuse midline gliomas (DMG), including diffuse intrinsic pontine glioma (DIPG), have extremely poor outcomes with a median overall survival of 9–12 months from initial diagnosis. Standard-of-care is limited to focal radiation therapy, given the paucity of effective targeted therapies for DMG. To identify effective drugs for treatment of children diagnosed with DMG, we investigated the brain-penetrating multi cyclin-dependent kinase inhibitor Zotiraciclib (ZTR/TG02). ZTR has demonstrated encouraging response rates and a benign safety profile in phase 1 trials of adults with high-grade glioma. It is thought to achieve its anti-cancer activity mainly by transcription disruption, a previously described vulnerability of DMGs, by inhibiting multiple cyclin-dependent kinases 9 and 7 (CDK9, 7). We found that ZTR robustly reduces viability of different patient derived DMG cells in a dose-dependent manner, with a median IC50 of 201 nM across eight tested cell lines (range 11–1258 nM, 72 hrs). Consistently, we observed loss of RNA polymerase II phosphorylation after 24 hours of treatment, indicating effective CDK9 inhibition at low drug concentrations and after short incubation time. This effect was followed by depletion of short-lived proteins including MYC and the anti-apoptotic factor MCL-1. Putative biomarkers of response and resistance were identified in silico using DepMap data analysis. To assess the safety profile of ZTR, we exposed our zebrafish model to various drug concentrations and found the drug to be safe at IC50 molarity. Ongoing in vitro and in vivo studies evaluating the efficacy of ZTR in combination with promising combination therapies for more effective treatment of children with DMG are also underway.
Collapse
Affiliation(s)
- Timothy Mueller
- DMG Research Center Zurich, Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children’s National Hospital, Washington, DC, USA
| | - Sandra Laternser
- DMG Research Center Zurich, Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Chiara Cianciolo
- DMG Research Center Zurich, Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Justyna Przystal
- DMG Research Center Zurich, Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Erin Bonner
- DMG Research Center Zurich, Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
- Center for Genetic Medicine Research, Children’s National Hospital, Washington, DC, USA
| | - Matt C Biery
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Nicholas A Vitanza
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Washington, Seattle Children’s Hospital, Seattle, WA, USA
| | - Michael Grotzer
- DMG Research Center Zurich, Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | - Sabine Mueller
- DMG Research Center Zurich, Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
- UCSF Department of Neurology, Neurosurgery and Pediatrics, San Francisco, CA, USA
| | - Javad Nazarian
- DMG Research Center Zurich, Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
- Center for Genetic Medicine Research, Children’s National Hospital, Washington, DC, USA
| |
Collapse
|
13
|
Bailey CP, Figueroa M, Gangadharan A, Yang Y, Romero MM, Kennis BA, Yadavilli S, Henry V, Collier T, Monje M, Lee DA, Wang L, Nazarian J, Gopalakrishnan V, Zaky W, Becher OJ, Chandra J. Pharmacologic inhibition of lysine-specific demethylase 1 as a therapeutic and immune-sensitization strategy in pediatric high-grade glioma. Neuro Oncol 2021; 22:1302-1314. [PMID: 32166329 DOI: 10.1093/neuonc/noaa058] [Citation(s) in RCA: 39] [Impact Index Per Article: 13.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Diffuse midline gliomas (DMG), including brainstem diffuse intrinsic pontine glioma (DIPG), are incurable pediatric high-grade gliomas (pHGG). Mutations in the H3 histone tail (H3.1/3.3-K27M) are a feature of DIPG, rendering them therapeutically sensitive to small-molecule inhibition of chromatin modifiers. Pharmacological inhibition of lysine-specific demethylase 1 (LSD1) is clinically relevant but has not been carefully investigated in pHGG or DIPG. METHODS Patient-derived DIPG cell lines, orthotopic mouse models, and pHGG datasets were used to evaluate effects of LSD1 inhibitors on cytotoxicity and immune gene expression. Immune cell cytotoxicity was assessed in DIPG cells pretreated with LSD1 inhibitors, and informatics platforms were used to determine immune infiltration of pHGG. RESULTS Selective cytotoxicity and an immunogenic gene signature were established in DIPG cell lines using clinically relevant LSD1 inhibitors. Pediatric HGG patient sequencing data demonstrated survival benefit of this LSD1-dependent gene signature. Pretreatment of DIPG with these inhibitors increased lysis by natural killer (NK) cells. Catalytic LSD1 inhibitors induced tumor regression and augmented NK cell infusion in vivo to reduce tumor burden. CIBERSORT analysis of patient data confirmed NK infiltration is beneficial to patient survival, while CD8 T cells are negatively prognostic. Catalytic LSD1 inhibitors are nonperturbing to NK cells, while scaffolding LSD1 inhibitors are toxic to NK cells and do not induce the gene signature in DIPG cells. CONCLUSIONS LSD1 inhibition using catalytic inhibitors is selectively cytotoxic and promotes an immune gene signature that increases NK cell killing in vitro and in vivo, representing a therapeutic opportunity for pHGG. KEY POINTS 1. LSD1 inhibition using several clinically relevant compounds is selectively cytotoxic in DIPG and shows in vivo efficacy as a single agent.2. An LSD1-controlled gene signature predicts survival in pHGG patients and is seen in neural tissue from LSD1 inhibitor-treated mice.3. LSD1 inhibition enhances NK cell cytotoxicity against DIPG in vivo and in vitro with correlative genetic biomarkers.
Collapse
Affiliation(s)
- Cavan P Bailey
- Department of Pediatrics , Research, The MD Anderson Cancer Center, Houston, Texas.,Department of Epigenetics and Molecular Carcinogenesis, The MD Anderson Cancer Center, Houston, Texas.,Center for Cancer Epigenetics, The MD Anderson Cancer Center, Houston, Texas
| | - Mary Figueroa
- Department of Pediatrics , Research, The MD Anderson Cancer Center, Houston, Texas.,Department of Epigenetics and Molecular Carcinogenesis, The MD Anderson Cancer Center, Houston, Texas.,Center for Cancer Epigenetics, The MD Anderson Cancer Center, Houston, Texas
| | - Achintyan Gangadharan
- Department of Pediatrics , Research, The MD Anderson Cancer Center, Houston, Texas.,Department of Epigenetics and Molecular Carcinogenesis, The MD Anderson Cancer Center, Houston, Texas
| | - Yanwen Yang
- Department of Pediatrics , Research, The MD Anderson Cancer Center, Houston, Texas
| | - Megan M Romero
- Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, Illinois
| | - Bridget A Kennis
- Department of Pediatrics , Research, The MD Anderson Cancer Center, Houston, Texas
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC
| | - Verlene Henry
- Department of Pediatrics , Research, The MD Anderson Cancer Center, Houston, Texas
| | - Tiara Collier
- Brain Tumor Center, The MD Anderson Cancer Center, Houston, Texas
| | - Michelle Monje
- Department of Neurology and Neurological Sciences, Stanford University, Palo Alto, California
| | - Dean A Lee
- Department of Pediatrics, Nationwide Children's and the Ohio State Comprehensive Cancer Center, Columbus, Ohio
| | - Linghua Wang
- Department of Genomic Medicine, The MD Anderson Cancer Center, Houston, Texas
| | - Javad Nazarian
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC
| | - Vidya Gopalakrishnan
- The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, Texas.,Center for Cancer Epigenetics, The MD Anderson Cancer Center, Houston, Texas
| | - Wafik Zaky
- Department of Pediatrics , Research, The MD Anderson Cancer Center, Houston, Texas
| | - Oren J Becher
- Department of Pediatrics, Northwestern Feinberg School of Medicine, Chicago, Illinois
| | - Joya Chandra
- Department of Pediatrics , Research, The MD Anderson Cancer Center, Houston, Texas.,Department of Epigenetics and Molecular Carcinogenesis, The MD Anderson Cancer Center, Houston, Texas.,Center for Cancer Epigenetics, The MD Anderson Cancer Center, Houston, Texas
| |
Collapse
|
14
|
Adorno JO, Hover L, He C, Zhu X, Goldhamer D, Carcaboso A, Yadavilli S, Nazarian J, Baker S. DIPG-51. ACVR1 MUTATIONS PROMOTE TUMOR GROWTH IN MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro Oncol 2020. [PMCID: PMC7715394 DOI: 10.1093/neuonc/noaa222.096] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Mutations in the gene encoding activin A receptor type 1 (ACVR1) are found in approximately 25% of diffuse intrinsic pontine gliomas (DIPGs), a pediatric glioma with 2-year survival rate of less than 10%. ACVR1mutations frequently coincide with activating PIK3CA or PIK3R1 mutations, indicating a potential cooperative effect of BMP and PI3K signaling in gliomagenesis. We used genetically engineered mice with inducible knock-in of Acvr1R206H or Pik3caE545K alleles, such that cre-mediated recombination resulted in expression of the gain of function mutated genes from their endogenous promoters at physiological levels. Cre-mediated deletion in GFAP-CreER;Pik3caE545K/+;p53cKO mice (Pik3ca;p53) mediated Trp53 deletion and expression of Pik3caE545K in glial progenitors, and spontaneously induced high-grade glioma (HGG) in mice with complete penetrance. Heterozygous knock-in of the Acvr1R206H allele accelerated tumorigenesis and impaired survival in Pik3ca;p53 mice (Acvr1;Pik3ca;p53). Transcriptomic analysis of Acvr1;Pik3ca;p53 tumors compared to Pik3ca;p53 littermate controls, as in patient-derived tumors, revealed broad molecular signatures associated with cell fate commitment and chromosome maintenance. Pharmacologic inhibition of ACVR1 was sufficient to impair growth in human patient-derived DIPG cell lines. Together, our studies show that ACVR1 activation promotes tumor growth in spontaneous mouse HGG and patient-derived DIPG cells, suggesting that ACVR1 inhibition may produce a clinically significant therapeutic effect in DIPG.
Collapse
Affiliation(s)
| | - Laura Hover
- St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Chen He
- St. Jude Children’s Research Hospital, Memphis, TN, USA
| | - Xiaoyan Zhu
- St. Jude Children’s Research Hospital, Memphis, TN, USA
| | | | - Angel Carcaboso
- Institut de Recerca Sant Joan de Deu, Barcelona, Spain
- Hospital Sant Joan de Deu, Barcelona, Spain
| | | | - Javad Nazarian
- Children’s National Health System, Washington DC, USA
- George Washington University, Washington DC, USA
| | - Suzanne Baker
- St. Jude Children’s Research Hospital, Memphis, TN, USA
| |
Collapse
|
15
|
Przystal J, Yadavilli S, Abadi CC, Yadav VN, Laternser S, Cosentino CC, Waszak S, Cartaxo R, Biery M, Myers C, Jayasekara S, Olson J, Filbin M, Vitanza N, Cain J, Koschmann C, Mueller S, Nazarian J. DDRE-03. INTERNATIONAL PRECLINICAL DRUG DISCOVERY AND BIOMARKER PROGRAM INFORMING AN ADOPTIVE COMBINATORIAL TRIAL FOR DIFFUSE MIDLINE GLIOMAS. Neuro Oncol 2020. [DOI: 10.1093/neuonc/noaa215.248] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
INTRODUCTION
DMG-ACT (DMG- multi-arm Adaptive and Combinatorial Trial) aims to implement a highly innovative clinical trial design of combinatorial arms for patients with diffuse midline gliomas (DMGs) at all disease stages that is adaptive to pre-clinical data generated in ten collaborating institutions. Novel drug and drug combination were tested, predictive biomarkers were identified and incorporated in clinical trial design.
METHODS
In vitro (n=15) and in vivo (n=8) models of DMGs across ten institutions were used to assess single and combination treatments with ONC201, ONC206, marizomib, panobinostat, 5-Azacytidine, Val-083, GDC0084 and TAK228. In vivo drug toxicity screenings were conducted using larval zebrafish model and murine PDX models. Predictive biomarkers for ONC201 and ONC206 were identified using meta-analysis, and extensive molecular assays including CRISPR, RNAseq, FACS, and IHC.
RESULTS
Inhibitory concentrations (IC50) were established and validated multiple preclinical models. ONC201 and ONC206, ONC201 and TAK228, ONC201 and GDC0084 showed synergism. In vivo survival assays showed increased survival for: ONC201 (p=0.01), ONC206 (p=0.01), ONC201+ONC206 (p=0.02), and ONC201+panobinostat (p=0.01). Marizomib showed toxicity in murine/zebrafish PDXs models. Murine pharmacokinetic analysis showed peak brain levels of ONC201 and ONC206 above pre-clinical IC50. Molecular testing and analyses of existing drug screen across 537 cancer cell lines validated mitochondrial protease ClpP and ATF4 as ONC201/6 targets. Predictive biomarkers of response to drug were identified.
CONCLUSION
Thorough preclinical testing in a multi-site laboratory setting is feasible and identified ONC201 in combination with ONC206, TAK228 and GDC0084 as promising therapeutics for DMGs.
Collapse
Affiliation(s)
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children’s National Medical Center, Washington, DC, USA
| | | | | | - Sandra Laternser
- Oncology Department, University Children’s Hospital Zurich, Zurich, Switzerland
| | | | | | | | - Matt Biery
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Carrie Myers
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Samantha Jayasekara
- Developmental and Cancer Biology Centre for Cancer Research Hudson Institute of Medical Research, Melbourne, Australia
| | - James Olson
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Mariella Filbin
- Dana-Farber Boston Children’s Cancer and Blood Disorders Center, Boston, MA, USA
| | | | - Jason Cain
- Developmental and Cancer Biology Centre for Cancer Research Hudson Institute of Medical Research, Melbourne, Australia
| | - Carl Koschmann
- University of Michigan Medical School, Ann Abor, MI, USA
| | - Sabine Mueller
- University of California, San Francisco, San Francisco, CA, USA
| | | |
Collapse
|
16
|
Kambhampati M, Panditharatna E, Yadavilli S, Saoud K, Lee S, Eze A, Almira-Suarez MI, Hancock L, Bonner ER, Gittens J, Stampar M, Gaonkar K, Resnick AC, Kline C, Ho CY, Waanders AJ, Georgescu MM, Rance NE, Kim Y, Johnson C, Rood BR, Kilburn LB, Hwang EI, Mueller S, Packer RJ, Bornhorst M, Nazarian J. Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. Sci Rep 2020; 10:10954. [PMID: 32616776 PMCID: PMC7331588 DOI: 10.1038/s41598-020-67764-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2020] [Accepted: 06/11/2020] [Indexed: 01/23/2023] Open
Abstract
Children diagnosed with brain tumors have the lowest overall survival of all pediatric cancers. Recent molecular studies have resulted in the discovery of recurrent driver mutations in many pediatric brain tumors. However, despite these molecular advances, the clinical outcomes of high grade tumors, including H3K27M diffuse midline glioma (H3K27M DMG), remain poor. To address the paucity of tissue for biological studies, we have established a comprehensive protocol for the coordination and processing of donated specimens at postmortem. Since 2010, 60 postmortem pediatric brain tumor donations from 26 institutions were coordinated and collected. Patient derived xenograft models and cell cultures were successfully created (76% and 44% of attempts respectively), irrespective of postmortem processing time. Histological analysis of mid-sagittal whole brain sections revealed evidence of treatment response, immune cell infiltration and the migratory path of infiltrating H3K27M DMG cells into other midline structures and cerebral lobes. Sequencing of primary and disseminated tumors confirmed the presence of oncogenic driver mutations and their obligate partners. Our findings highlight the importance of postmortem tissue donations as an invaluable resource to accelerate research, potentially leading to improved outcomes for children with aggressive brain tumors.
Collapse
Affiliation(s)
- Madhuri Kambhampati
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.,Brain Tumor Institute, Children's National Hospital, Washington, DC, USA
| | - Eshini Panditharatna
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.,Brain Tumor Institute, Children's National Hospital, Washington, DC, USA.,Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.,Brain Tumor Institute, Children's National Hospital, Washington, DC, USA
| | - Karim Saoud
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.,Brain Tumor Institute, Children's National Hospital, Washington, DC, USA
| | - Sulgi Lee
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.,Brain Tumor Institute, Children's National Hospital, Washington, DC, USA.,The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Augustine Eze
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.,Brain Tumor Institute, Children's National Hospital, Washington, DC, USA
| | - M I Almira-Suarez
- Department of Pathology, Children's National Hospital, Washington, DC, USA.,The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Lauren Hancock
- Brain Tumor Institute, Children's National Hospital, Washington, DC, USA.,Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA
| | - Erin R Bonner
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.,Brain Tumor Institute, Children's National Hospital, Washington, DC, USA.,The George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Jamila Gittens
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA.,PTC Therapeutics, South Plainfield, NJ, USA
| | - Mojca Stampar
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA
| | - Krutika Gaonkar
- Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Adam C Resnick
- Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Cassie Kline
- Pediatric Hematology-Oncology and Neurology, UCSF Benioff Children's Hospital, San Francisco, CA, USA.,Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA
| | - Cheng-Ying Ho
- Department of Pathology and Neurology, University of Maryland School of Medicine, Baltimore, MD, USA
| | - Angela J Waanders
- Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
| | | | - Naomi E Rance
- Department of Pathology, University of Arizona College of Medicine, Tucson, AZ, USA
| | - Yong Kim
- Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD, USA
| | - Courtney Johnson
- Brain Tumor Institute, Children's National Hospital, Washington, DC, USA
| | - Brian R Rood
- Brain Tumor Institute, Children's National Hospital, Washington, DC, USA.,Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA
| | - Lindsay B Kilburn
- Brain Tumor Institute, Children's National Hospital, Washington, DC, USA.,Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA
| | - Eugene I Hwang
- Brain Tumor Institute, Children's National Hospital, Washington, DC, USA.,Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA
| | - Sabine Mueller
- Pediatric Hematology-Oncology and Neurology, UCSF Benioff Children's Hospital, San Francisco, CA, USA.,Department of Oncology, Children's Research Center, University Children's Hospital Zürich, Zurich, Switzerland
| | - Roger J Packer
- Brain Tumor Institute, Children's National Hospital, Washington, DC, USA
| | - Miriam Bornhorst
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA. .,Brain Tumor Institute, Children's National Hospital, Washington, DC, USA. .,The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
| | - Javad Nazarian
- Center for Genetic Medicine Research, Children's National Hospital, Washington, DC, USA. .,Department of Oncology, Children's Research Center, University Children's Hospital Zürich, Zurich, Switzerland. .,The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.
| |
Collapse
|
17
|
Lee S, Kambhampati M, Yadavilli S, Gordish-Dressman H, Santi M, Cruz CR, Packer RJ, Almira-Suarez MI, Hwang EI, Nazarian J. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma. J Neuropathol Exp Neurol 2020; 78:380-388. [PMID: 30990879 PMCID: PMC6467196 DOI: 10.1093/jnen/nlz021] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
Diffuse intrinsic pontine gliomas (DIPGs) are deadly tumors comprising 10%–15% of all childhood CNS cancers. Standard treatment is considered palliative and prognosis is near universal mortality. DIPGs have been classified into genomic subtypes based on histone variants with the lysine to methionine mutation on position 27 of histone tails (K27M). Given the increasing promise of immunotherapy, there have been ongoing efforts to identify tumor-specific antigens to serve as immunologic targets. We evaluated a large cohort of CNS specimens for Wilms’ tumor protein (WT1) expression. These specimens include primary pediatric CNS tumors (n = 38 midline gliomas and n = 3 non-midline gliomas; n = 23 DIPG, n = 10 low-grade gliomas, n = 8 high-grade gliomas), and DIPG primary cells. Here, we report the validation of WT1 as a tumor-associated antigen in DIPGs. We further report that WT1 expression is significantly correlated with specific oncohistone variants, with the highest expression detected in the H3.3K27M subgroup. WT1 expression was absent in all control specimens (n = 21). Western blot assays using DIPG primary cells (n = 6) showed a trend of higher WT1 expression in H3.3K27M cells when compared with H3.1 K27M cells and H3 wildtype cells. Our data are the first indication of the association between WT1 and DIPG, with specific upregulation in those harboring oncohistone H3.3K27M.
Collapse
Affiliation(s)
- Sulgi Lee
- Children's National Health System, Center for Genetic Medicine Research, Washington, District of Columbia.,The George Washington University School of Medicine and Health Sciences, Institute for Biomedical Sciences, Washington
| | - Madhuri Kambhampati
- Children's National Health System, Center for Genetic Medicine Research, Washington, District of Columbia
| | - Sridevi Yadavilli
- Children's National Health System, Center for Genetic Medicine Research, Washington, District of Columbia
| | - Heather Gordish-Dressman
- Children's National Health System, Center for Genetic Medicine Research, Washington, District of Columbia
| | - Mariarita Santi
- Department of Pathology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
| | - Conrad R Cruz
- Children's National Health System, Center for Cancer and Immunology Research, Washington, District of Columbia
| | - Roger J Packer
- Children's National Health System, Brain Tumor Institute, Washington, District of Columbia
| | - M Isabel Almira-Suarez
- Department of Pathology and Laboratory Medicine, Children's National Health System, Washington, District of Columbia (MIA-S)
| | - Eugene I Hwang
- Children's National Health System, Brain Tumor Institute, Washington, District of Columbia
| | - Javad Nazarian
- Children's National Health System, Center for Genetic Medicine Research, Washington, District of Columbia.,The George Washington University School of Medicine and Health Sciences, Institute for Biomedical Sciences, Washington.,Children's National Health System, Brain Tumor Institute, Washington, District of Columbia.,Department of Genomics and Precision Medicine, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia
| |
Collapse
|
18
|
Fincher JA, Korte AR, Dyer JE, Yadavilli S, Morris NJ, Jones DR, Shanmugam VK, Pirlo RK, Vertes A. Mass spectrometry imaging of triglycerides in biological tissues by laser desorption ionization from silicon nanopost arrays. J Mass Spectrom 2020; 55:e4443. [PMID: 31524963 DOI: 10.1002/jms.4443] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/08/2019] [Revised: 08/31/2019] [Accepted: 09/10/2019] [Indexed: 06/10/2023]
Abstract
Mass spectrometry imaging (MSI) is used increasingly to simultaneously detect a broad range of biomolecules while mapping their spatial distributions within biological tissue sections. Matrix-assisted laser desorption ionization (MALDI) is recognized as the method-of-choice for MSI applications due in part to its broad molecular coverage. In spite of the remarkable advantages offered by MALDI, imaging of neutral lipids, such as triglycerides (TGs), from tissue has remained a significant challenge due to ion suppression of TGs by phospholipids, e.g. phosphatidylcholines (PCs). To help overcome this limitation, silicon nanopost array (NAPA) substrates were introduced to selectively ionize TGs from biological tissue sections. This matrix-free laser desorption ionization (LDI) platform was previously shown to provide enhanced ionization of certain lipid classes, such as hexosylceramides (HexCers) and phosphatidylethanolamines (PEs) from mouse brain tissue. In this work, we present NAPA as an MSI platform offering enhanced ionization efficiency for TGs from biological tissues relative to MALDI, allowing it to serve as a complement to MALDI-MSI. Analysis of a standard lipid mixture containing PC(18:1/18:1) and TG(16:0/16:0/16:0) by LDI from NAPA provided an ~49 and ~227-fold higher signal for TG(16:0/16:0/16:0) relative to MALDI, when analyzed without and with the addition of a sodium acetate, respectively. In contrast, MALDI provided an ~757 and ~295-fold higher signal for PC(18:1/18:1) compared with NAPA, without and with additional Na+ . Averaged signal intensities for TGs from MSI of mouse lung and human skin tissues exhibited an ~105 and ~49-fold increase, respectively, with LDI from NAPA compared with MALDI. With respect to PCs, MALDI provided an ~2 and ~19-fold increase in signal intensity for mouse lung and human skin tissues, respectively, when compared with NAPA. The complementary coverage obtained by the two platforms demonstrates the utility of using both techniques to maximize the information obtained from lipid MS or MSI experiments.
Collapse
Affiliation(s)
- Jarod A Fincher
- Department of Chemistry, The George Washington University, Washington, DC, 20052, USA
| | - Andrew R Korte
- Department of Chemistry, The George Washington University, Washington, DC, 20052, USA
| | - Jacqueline E Dyer
- Department of Chemistry, The George Washington University, Washington, DC, 20052, USA
| | - Sridevi Yadavilli
- Research Center for Genetic Medicine, Children's National Medical Center, Washington, DC, 20010, USA
| | | | - Derek R Jones
- Division of Rheumatology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, 20037, USA
| | - Victoria K Shanmugam
- Division of Rheumatology, School of Medicine and Health Sciences, The George Washington University, Washington, DC, 20037, USA
| | - Russel K Pirlo
- Chemistry Division, U.S. Naval Research Laboratory, Washington, DC, 20375, USA
| | - Akos Vertes
- Department of Chemistry, The George Washington University, Washington, DC, 20052, USA
| |
Collapse
|
19
|
Angevin E, Groenland S, Bauer T, Rischin D, Gardeazabal I, Moreno V, Trigo J, Chisamore M, Shaik J, Rigat F, Ellis C, Chen H, Gagnon R, Scherer S, Turner D, Yadavilli S, Ballas M, Hoos A, Maio M. 11P Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.01.059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
20
|
Fincher JA, Korte AR, Yadavilli S, Morris NJ, Vertes A. Multimodal imaging of biological tissues using combined MALDI and NAPA-LDI mass spectrometry for enhanced molecular coverage. Analyst 2020; 145:6910-6918. [DOI: 10.1039/d0an00836b] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Sequential imaging of a tissue section by MALDI and NAPA-LDI mass spectrometry provides enhanced molecular coverage.
Collapse
Affiliation(s)
- Jarod A. Fincher
- Department of Chemistry
- The George Washington University
- Washington
- USA
| | - Andrew R. Korte
- Department of Chemistry
- The George Washington University
- Washington
- USA
| | - Sridevi Yadavilli
- Research Center for Genetic Medicine
- Children's National Medical Center
- Washington
- USA
| | | | - Akos Vertes
- Department of Chemistry
- The George Washington University
- Washington
- USA
| |
Collapse
|
21
|
Maio M, Groenland S, Bauer T, Rischin D, Gardeazabal I, Moreno V, Trigo Perez J, Chisamore M, Sadik Shaik J, Rigat F, Ellis C, Chen H, Gagnon R, Scherer S, Turner D, Yadavilli S, Ballas M, Hoos A, Angevin E. Pharmacokinetic/ pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz268.098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
22
|
Spigel D, Garassino M, Besse B, Sacher A, Barve M, Cousin S, Schenker M, Rogan D, Yadavilli S, Acusta A, Amit O, Leighton-Swayze A, Ballas M, Hoos A, Reck M. P1.01-110 Novel Regimens Versus Standard-of-Care in NSCLC: A Phase II, Randomized, Open-Label, Platform Trial Using a Master Protocol. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|
23
|
Powell AB, Yadavilli S, Saunders D, Van Pelt S, Chorvinsky E, Burga RA, Albihani S, Hanley PJ, Xu Z, Pei Y, Yvon ES, Hwang EI, Bollard CM, Nazarian J, Cruz CRY. Medulloblastoma rendered susceptible to NK-cell attack by TGFβ neutralization. J Transl Med 2019; 17:321. [PMID: 31547819 PMCID: PMC6757414 DOI: 10.1186/s12967-019-2055-4] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Accepted: 08/31/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Medulloblastoma (MB), the most common pediatric brain cancer, presents with a poor prognosis in a subset of patients with high risk disease, or at recurrence, where current therapies are ineffective. Cord blood (CB) natural killer (NK) cells may be promising off-the-shelf effector cells for immunotherapy due to their recognition of malignant cells without the need for a known target, ready availability from multiple banks, and their potential to expand exponentially. However, they are currently limited by immune suppressive cytokines secreted in the MB tumor microenvironment including Transforming Growth Factor β (TGF-β). Here, we address this challenge in in vitro models of MB. METHODS CB-derived NK cells were modified to express a dominant negative TGF-β receptor II (DNRII) using retroviral transduction. The ability of transduced CB cells to maintain function in the presence of medulloblastoma-conditioned media was then assessed. RESULTS We observed that the cytotoxic ability of nontransduced CB-NK cells was reduced in the presence of TGF-β-rich, medulloblastoma-conditioned media (21.21 ± 1.19% killing at E:T 5:1 in the absence vs. 14.98 ± 2.11% in the presence of medulloblastoma-conditioned media, n = 8, p = 0.02), but was unaffected in CB-derived DNRII-transduced NK cells (21.11 ± 1.84% killing at E:T 5:1 in the absence vs. 21.81 ± 3.37 in the presence of medulloblastoma-conditioned media, n = 8, p = 0.85. We also observed decreased expression of CCR2 in untransduced NK cells (mean CCR2 MFI 826 ± 117 in untransduced NK + MB supernatant from mean CCR2 MFI 1639.29 ± 215 in no MB supernatant, n = 7, p = 0.0156), but not in the transduced cells. Finally, we observed that CB-derived DNRII-transduced NK cells may protect surrounding immune cells by providing a cytokine sink for TGF-β (decreased TGF-β levels of 610 ± 265 pg/mL in CB-derived DNRII-transduced NK cells vs. 1817 ± 342 pg/mL in untransduced cells; p = 0.008). CONCLUSIONS CB NK cells expressing a TGF-β DNRII may have a functional advantage over unmodified NK cells in the presence of TGF-β-rich MB, warranting further investigation on its potential applications for patients with medulloblastoma.
Collapse
Affiliation(s)
- Allison B Powell
- George Washington University Cancer Center, George Washington University, Washington, DC, USA
| | - Sridevi Yadavilli
- Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, USA
| | - Devin Saunders
- Center for Cancer and Immunology Research, Children's National Medical Center, 111 Michigan Ave. NW, Washington, DC, 20010, USA
| | - Stacey Van Pelt
- George Washington University Cancer Center, George Washington University, Washington, DC, USA
| | - Elizabeth Chorvinsky
- Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, USA
| | - Rachel A Burga
- George Washington University Cancer Center, George Washington University, Washington, DC, USA
| | - Shuroug Albihani
- Center for Cancer and Immunology Research, Children's National Medical Center, 111 Michigan Ave. NW, Washington, DC, 20010, USA
| | - Patrick J Hanley
- Center for Cancer and Immunology Research, Children's National Medical Center, 111 Michigan Ave. NW, Washington, DC, 20010, USA
| | - Zhenhua Xu
- Center for Cancer and Immunology Research, Children's National Medical Center, 111 Michigan Ave. NW, Washington, DC, 20010, USA
| | - Yanxin Pei
- Center for Cancer and Immunology Research, Children's National Medical Center, 111 Michigan Ave. NW, Washington, DC, 20010, USA
| | - Eric S Yvon
- George Washington University Cancer Center, George Washington University, Washington, DC, USA
| | - Eugene I Hwang
- Center for Cancer and Immunology Research, Children's National Medical Center, 111 Michigan Ave. NW, Washington, DC, 20010, USA
| | - Catherine M Bollard
- George Washington University Cancer Center, George Washington University, Washington, DC, USA.,Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, USA
| | - Javad Nazarian
- Center for Genetic Medicine Research, Children's National Medical Center, Washington, DC, USA
| | - Conrad Russell Y Cruz
- George Washington University Cancer Center, George Washington University, Washington, DC, USA. .,Center for Cancer and Immunology Research, Children's National Medical Center, 111 Michigan Ave. NW, Washington, DC, 20010, USA.
| |
Collapse
|
24
|
Kambhampati M, Panditharatna E, Yadavilli S, Ho CY, Almira-Suarez I, Bornhorst M, Kilburn L, Hwang E, Rood B, Georgescu MM, Rance N, Mueller S, Packer R, Nazarian J. DIPG-33. HARMONIZATION AND CHARACTERIZATION OF POSTMORTEM DONATIONS FOR PEDIATRIC BRAIN TUMORS. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | | | | | | | | | | | | | - Eugene Hwang
- Children’s National Health System, Washington DC, USA
| | - Brian Rood
- Children’s National Health System, Washington DC, USA
| | | | | | - Sabine Mueller
- University of California San Francisco, San Francisco, CA, USA
| | - Roger Packer
- Children’s National Health System, Washington DC, USA
| | | |
Collapse
|
25
|
Lee S, Kambhampati M, Yadavilli S, Gordish-Dressman H, Gaonkar K, Raman P, Cruz C, Packer R, Almira-Suarez MI, Becher O, Resnick A, Mueller S, Hwang E, Nazarian J. DIPG-30. ISOFORM SPECIFIC OVEREXPRESSION OF WILMS’ TUMOR PROTEIN IN DIFFUSE INTRINSIC PONTINE GLIOMAS. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Sulgi Lee
- Children’s National Health System, Washington DC, USA
- The George Washington University, Washington DC, USA
| | | | | | - Heather Gordish-Dressman
- Children’s National Health System, Washington DC, USA
- The George Washington University, Washington DC, USA
| | | | - Pichai Raman
- Children’s Hospital of Philadelphia, Philadelphia, PA, USA
| | - Conrad Cruz
- Children’s National Health System, Washington DC, USA
| | - Roger Packer
- Children’s National Health System, Washington DC, USA
| | | | | | - Adam Resnick
- Children’s Hospital of Philadelphia, Philadelphia, PA, USA
| | - Sabine Mueller
- University of California San Francisco, San Francisco, CA, USA
| | - Eugene Hwang
- Children’s National Health System, Washington DC, USA
| | - Javad Nazarian
- Children’s National Health System, Washington DC, USA
- The George Washington University, Washington DC, USA
| |
Collapse
|
26
|
Kim YY, Andricovich J, Yadavilli S, Kambhampati M, Mueller S, Tzatsos A, Nazarian J. DIPG-32. COMBINATION OF ChIP-SEQ AND RNA-SEQ ANALYSIS FOR TARGET DISCOVERY REVEAL PROMISING CANDIDATES FOR VALIDATION. Neuro Oncol 2019. [DOI: 10.1093/neuonc/noz036.053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Yong Yean Kim
- Children’s National Medical Center, Washington, DC, USA
| | | | | | | | - Sabine Mueller
- University of California San Francisco, San Francisco, CA, USA
| | | | | |
Collapse
|
27
|
Fincher JA, Dyer JE, Korte AR, Yadavilli S, Morris NJ, Vertes A. Matrix‐free mass spectrometry imaging of mouse brain tissue sections on silicon nanopost arrays. J Comp Neurol 2018; 527:2101-2121. [DOI: 10.1002/cne.24566] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/14/2018] [Revised: 10/12/2018] [Accepted: 10/15/2018] [Indexed: 12/19/2022]
Affiliation(s)
- Jarod A. Fincher
- George Washington University Washington District of Columbia 20052
| | | | - Andrew R. Korte
- George Washington University Washington District of Columbia 20052
| | - Sridevi Yadavilli
- Research Center for Genetic Medicine Children's National Medical Center Washington District of Columbia 20010
| | | | - Akos Vertes
- George Washington University Washington District of Columbia 20052
| |
Collapse
|
28
|
Lee S, Kambhampati M, Yadavilli S, Gordish-Dressman H, Santi M, Cruz C, Packer R, Almira-Suaurez I, Hwang E, Nazarian J. PDTM-15. IDENTIFICATION AND CHARACTERIZATION OF WILMS’ TUMOR PROTEIN IN PEDIATRIC MIDLINE GLIOMAS. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy148.857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Sulgi Lee
- The George Washington University, Washington, DC, USA
| | | | | | | | - Mariarita Santi
- Department of Anatomic Pathology and Laboratory Medicine, Childrens Hospital of Philadelphia, Philadelphia, Philadelphia, PA, USA
| | - Conrad Cruz
- Childrens National Health System, Washington, DC, USA
| | - Roger Packer
- Children’s National Medical Center, Washington, DC, USA
| | | | - Eugene Hwang
- Childrens National Health System, Washington, DC, USA
| | | |
Collapse
|
29
|
Hansen A, Bauer T, Moreno V, Maio M, Groenland S, Martin-Liberal J, Gan H, Rischin D, Millward M, Olszanski A, Cho D, Paul E, Ballas M, Ellis C, Zhou H, Yadavilli S, Sadik Shaik J, Schmidt E, Hoos A, Angevin E. First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy288.011] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Brett S, Yadavilli S, Seestaller-Wehr L, Bhattacharya S, Jackson H, Bi M, Willoughby J, Zhang T, Liu YB, Katlinskaya Y, Shi H, Jing J, Hahn A, Speller S, David Figueroa D, Yu J, Olive D, Cragg M, Mayes P, Hoos A. Preclinical evaluation of a non-depleting, first-in-class humanized IgG4 agonist anti-ICOS antibody. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy303.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Kim YY, Andricovich J, Yadavilli S, Kambhampati M, Tzatsos A, Nazarian J. DIPG-50. CHROMATIN IMMUNOPRECIPITATION OF DIFFUSE INTRINSIC PONTINE GLIOMA TUMOR TISSUE IS FEASIBLE AND SHOW DIFFERENT ENRICHMENT COMPARED TO PRIMARY CELL LINE. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Yong Yean Kim
- Children’s National Medical Center, Washington, DC, USA
| | | | | | | | | | | |
Collapse
|
32
|
Lee S, Kambhampati M, Yadavilli S, Santi M, Packer RJ, Cruz CR, Almira I, Hwang E, Nazarian J. DIPG-58. SUBTYPE-SPECIFIC OVEREXPRESSION OF WILMS’ TUMOR PROTEIN IN PEDIATRIC MIDLINE HIGH GRADE GLIOMAS. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.151] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Sulgi Lee
- Children’s National Health System, Washington, DC, USA
- The George Washington University, Washington, DC, USA
| | | | | | | | | | - Conrad R Cruz
- Children’s National Health System, Washington, DC, USA
- The George Washington University, Washington, DC, USA
| | - Isabel Almira
- Children’s National Health System, Washington, DC, USA
| | - Eugene Hwang
- Children’s National Health System, Washington, DC, USA
| | - Javad Nazarian
- Children’s National Health System, Washington, DC, USA
- The George Washington University, Washington, DC, USA
| |
Collapse
|
33
|
Yadavilli S, Knudson K, Kambhampati M, Panditharatna E, Prados M, Mueller S, Magge S, Kilburn L, Hwang E, Packer R, Nazarian J. HGG-38. DEVELOPMENT AND COMPREHENSIVE CHARACTERIZATION AND UTILIZATION OF PRECLINICAL MODELS OF PEDIATRIC HIGH GRADE GLIOMAS. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.310] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - Kathleen Knudson
- George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | | | - Eshini Panditharatna
- Children’s National Health System, Washington, DC, USA
- George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Michael Prados
- University of California, San Francisco School of Medicine, San Francisco, CA, USA
| | - Sabine Mueller
- University of California, San Francisco School of Medicine, San Francisco, CA, USA
| | - Suresh Magge
- Children’s National Health System, Washington, DC, USA
| | | | - Eugene Hwang
- Children’s National Health System, Washington, DC, USA
| | - Roger Packer
- Children’s National Health System, Washington, DC, USA
| | - Javad Nazarian
- Children’s National Health System, Washington, DC, USA
- George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| |
Collapse
|
34
|
Wells E, Kambhampati M, Damsker JM, Gordish-Dressman H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J. Vamorolone, a dissociative steroidal compound, reduces pro-inflammatory cytokine expression in glioma cells and increases activity and survival in a murine model of cortical tumor. Oncotarget 2018; 8:9366-9374. [PMID: 28030841 PMCID: PMC5354737 DOI: 10.18632/oncotarget.14070] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2016] [Accepted: 12/13/2016] [Indexed: 11/25/2022] Open
Abstract
Corticosteroids, such as dexamethasone, are routinely used as palliative care in neuro-oncology for their anti-inflammatory benefits, however many patients experience dose limiting side effects caused by glucocorticoid response element (GRE)-mediated transcription. The purpose of this study was to use a murine model to investigate a new steroid alternative, vamorolone, which promises to reduce side effects through dissociating GRE-mediated transcription and NF-κB -mediated anti-inflammatory actions. To compare vamorolone to dexamethasone in reducing pro-inflammatory signals in vitro, murine glioma cells were treated with dexamethasone, vamorolone or vehicle control. Changes in mRNA expression were assessed using the nanostring inflammatory platform. Furthermore, drug efficacy, post-treatment behavioral activity and side effects were assessed by treating two cohorts of brain tumor bearing mice with dexamethasone, vamorolone, or vehicle control. Our investigation showed that treatment with vamorolone resulted in a reduction of pro-inflammatory signals in tumor cells in vitro similar to treatment with dexamethasone. Treatment with vamorolone resulted in a better safety profile in comparison to dexamethasone treatment. Vamorolone- treated mice showed similar or better activity and survival when compared to dexamethasone-treated mice. Our data indicate vamorolone is a potential steroid-sparing alternative for treating patients with brain tumors.
Collapse
Affiliation(s)
- Elizabeth Wells
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA.,Brain Tumor Institute, Center for Neuroscience and Behavioral Medicine, Children's National Health System, Washington, DC, USA
| | - Madhuri Kambhampati
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA
| | | | | | - Sridevi Yadavilli
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA
| | | | - Jamila Gittens
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA
| | - Mojca Stampar
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA
| | - Roger J Packer
- Brain Tumor Institute, Center for Neuroscience and Behavioral Medicine, Children's National Health System, Washington, DC, USA
| | - Javad Nazarian
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA.,Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| |
Collapse
|
35
|
Knudson K, Yadavilli S, Packer R, Nazarian J. SCDT-30. SURGICAL IMPLANTATION OF AN OSMOTIC PUMP FOR CONVECTION ENHANCED DELIVERY INTO DIPG XENOGRAFT MURINE MODELS. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.1112] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Kambhampati M, Panditharatna E, Yadavilli S, Ho CY, Kilburn L, Hwang E, Rood B, Bornhorst M, Magge S, Gittens J, Clark M, Packer R, Nazarian J. TMIC-25. TUMOR MIGRATION AND ROLE OF MICROENVIRONMENT IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.1014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
37
|
Panditharatna E, Kambhampati M, Yadavilli S, Sandy J, Yang X, Kilburn L, Crawford J, Magge S, Packer R, Prados M, Mueller S, Nazarian J. GENE-43. LIQUID BIOPSY FOR MONITORING OF TUMOR RESPONSE IN CHILDREN WITH DIFFUSE MIDLINE GLIOMA. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox168.416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Gittens JS, Yadavilli S, Lin M, Panditharatna E, Magge SN, Packer RJ, Nazarian J. Abstract 5145: Demystification of obstacles encountered using convection enhanced delivery in preclinical models of diffuse intrinsic pontine glioma. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-5145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Diffuse intrinsic pontine glioma (DIPG) is a pediatric brain tumor that arises in the pons of the brainstem. The vital location of the tumor and the presence of the impermeable blood brain barrier (BBB) make treatments ineffective and leads to a high mortality rate of DIPG patients. Convection enhanced delivery (CED) is a promising drug delivery method because of its ability to bypass the BBB that is currently being investigated to deliver therapeutic agents directly to brain tumors. Nonetheless, clinical trials investigating the use of CED to treat patients have not shown prolonged patient survival. Previous studies have determined poor distribution in clinical studies due to reflux or back flow. Additionally, by analyzing the H&E and Ki67 stained brain sections of a DIPG patient that underwent CED, we determined that areas of radiation-induced necrosis within the tumor were a possible reason for treatment failure. In this study, we intend to optimize CED in orthotopic murine model of DIPG. Specifically, we have tested the ideal volume and rate of injection, as well as using the combined approach of using CED and radiation. Ideal injection rate was established by assessing infusion profiles in agarose brain phantoms using various needles, which resulted in the injection rate of 0.3ul/min producing the least back flow. Next, the ideal injection rate and volumes were tested in vivo by injecting non-tumor bearing mice with trypan blue. To assess the infusion rate, brain sections were analyzed at necropsy to determine distributions of the injected dye. To investigate accumulation of CED-mediated payload in necrotic sites, tumor bearing mice were exposed to radiation and then injected with the fluorescent dye, DiI. Formalin fixed brain sections were stained with DAPI and fluorescent images were taken. The results of this study indicate that a rate of 0.5ul/min results in a significantly larger distribution area compared to the 0.3ul/min injection rate (50.71 ± 4.84 compared to 30.47 ± 1.18, p=0.0462). Fluorescent images of brain sections of mice injected with DiI indicated the accumulation of dye in areas where there were no live cells, supporting the assumption that drug injections may be retreating to necrotic pockets and thus preventing equal distribution of the drug in the tumor. Ongoing studies include investigating the survival benefits of using CED to deliver therapeutic agents in tumor-bearing mice. Understanding the obstacles of convection enhanced delivery in murine models can help establish better treatment regimens and devices for patients and provide better preclinical models for drug testing.
Citation Format: Jamila S. Gittens, Sridevi Yadavilli, Michael Lin, Eshini Panditharatna, Suresh N. Magge, Roger J. Packer, Javad Nazarian. Demystification of obstacles encountered using convection enhanced delivery in preclinical models of diffuse intrinsic pontine glioma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5145. doi:10.1158/1538-7445.AM2017-5145
Collapse
Affiliation(s)
| | | | - Michael Lin
- 2The George Washington University, Washington, DC
| | | | | | | | | |
Collapse
|
39
|
Moser HH, Yoon S, Kambhampati M, Yadavilli S, Waanders AJ, Resnick A, Packer RJ, Nazarian J. Abstract 4887: Comprehensive molecular analysis of pediatric thalamic tumors. Cancer Res 2017. [DOI: 10.1158/1538-7445.am2017-4887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Childhood thalamic tumors are relatively rare cancers, accounting for 5% of all pediatric brain tumors and categorized as midline gliomas such as diffuse intrinsic pontine gliomas (DIPGs). We and others have shown that mutations in genes encoding for histone 3.3 (H3F3A), histone 3.2 (HIST2H3C) and histone 3.1 (HIST1H3B) along with their obligate partner mutations are the major driver mutations in DIPGs. Where recent studies have identified major histone partner mutations associated with DIPGs, more research is required to provide a clear landscape of genomic aberrations associated with thalamic tumors. We hypothesize that comprehensive whole genome sequence, methylation and proteome analysis of a large cohort of thalamic tumors will map differentially regulated pathways and identify potential novel driver and obligate partner mutations associated with thalamic gliomas. We have established a cohort (CNHS and CBTTC) of 128 thalamic specimens, including 56 pediatric and adolescent primary thalamic tumors with median age at diagnosis of 5.6 years (range 0-20 years); 40 normal controls with matched age and gender; and 32 midline tumors with potential thalamic involvement with median age at diagnosis of 7.6 years (range 0-19 years). Our cohort of primary thalamic tumors contained 31 (55.3%) and 19 (33.9%) tumors reviewed as high and low grade gliomas, respectively. From our midline tumors with potential thalamic involvement, 22 (68.7%) were classified as primary DIPG and 10 (31.2%) were other midline gliomas. Where available, MRI reviews and histopathological analysis were performed. Preliminary results showed that 7 of the extended tumors presented hypercellularity and positive histone 3 K27M staining, confirming that these tumors in fact extended to the thalamus as MRI showed. Additionally, Whole Exome Sequencing (WES) from one DIPG sample extending to the thalamus showed the same mutations found on the primary pons tumor: H3.1 K27M; ACVR1 G328V; PIK3CA H1047R; MAX R51Q and PTEN A126S. The remaining primary and extended thalamic tumors will be analyzed by WES to understand the molecular changes associated with this disease. In addition to our results, we analyzed the genomic landscape from pediatric thalamic tumors previously published (188), showing H3.3/H3.1 K27M (51%); BRAF (10.6%) and TP53 (8%) as the most frequent mutations among thalamic high and low grade astrocytomas. Further studies will allow us to compare comprehensive molecular analysis of thalamic tumors (primary and metastatic) and non-thalamic midline tumors (specimen and data already in hand) and identify similarities and differences in genomic, epigenomic and proteomic expression pattern which may guide a better characterization of thalamic tumor as a separate entity.
Citation Format: Heloisa H. Moser, Susanne Yoon, Madhuri Kambhampati, Sridevi Yadavilli, Angela J. Waanders, Adam Resnick, Roger J. Packer, Javad Nazarian. Comprehensive molecular analysis of pediatric thalamic tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 4887. doi:10.1158/1538-7445.AM2017-4887
Collapse
Affiliation(s)
| | - Susanne Yoon
- 1Childrens National Health System, Washington, DC
| | | | | | | | - Adam Resnick
- 2Children's Hospital of Philadelphia, Philadelphia, PA
| | | | | |
Collapse
|
40
|
Knudson K, Yadavilli S, Packer R, Nazarian J. DIPG-12. OPTIMIZATION OF OSMOTIC PUMP IMPLANTATION FOR DELIVERY OF THERAPEUTICS VIA CONVECTION ENHANCED DELIVERY IN PRECLINICAL MODELS OF DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
41
|
Panditharatna E, Sandy J, Kambhampati M, Yadavilli S, Kilburn L, Crawford J, Magge S, Packer RJ, Prados M, Mueller S, Nazarian J. DIPG-39. LIQUID BIOPSY FOR MONITORING OF TUMOR RESPONSE IN CHILDREN WITH MIDLINE GLIOMAS. Neuro Oncol 2017. [DOI: 10.1093/neuonc/nox083.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
42
|
Miyahara H, Yadavilli S, Natsumeda M, Rubens JA, Rodgers L, Kambhampati M, Taylor IC, Kaur H, Asnaghi L, Eberhart CG, Warren KE, Nazarian J, Raabe EH. The dual mTOR kinase inhibitor TAK228 inhibits tumorigenicity and enhances radiosensitization in diffuse intrinsic pontine glioma. Cancer Lett 2017; 400:110-116. [PMID: 28450157 DOI: 10.1016/j.canlet.2017.04.019] [Citation(s) in RCA: 43] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 03/13/2017] [Accepted: 04/19/2017] [Indexed: 11/18/2022]
Abstract
Diffuse intrinsic pontine glioma (DIPG) is an invasive and treatment-refractory pediatric brain tumor. Primary DIPG tumors harbor a number of mutations including alterations in PTEN, AKT, and PI3K and exhibit activation of mammalian Target of Rapamycin Complex 1 and 2 (mTORC1/2). mTORC1/2 regulate protein translation, cell growth, survival, invasion, and metabolism. Pharmacological inhibition of mTORC1 is minimally effective in DIPG. However, the activity of dual TORC kinase inhibitors has not been examined in this tumor type. Nanomolar levels of the mTORC1/2 inhibitor TAK228 reduced expression of p-AKTS473 and p-S6S240/244 and suppressed the growth of DIPG lines JHH-DIPG1, SF7761, and SU-DIPG-XIII. TAK228 induced apoptosis in DIPG cells and cooperated with radiation to further block proliferation and enhance apoptosis. TAK228 monotherapy inhibited the tumorigenicity of a murine orthotopic model of DIPG, more than doubling median survival (p = 0.0017) versus vehicle. We conclude that dual mTOR inhibition is a promising potential candidate for DIPG treatment.
Collapse
Affiliation(s)
- Hiroaki Miyahara
- Department of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Sridevi Yadavilli
- Research Center for Genetic Medicine, Children's National Health System, Washington, District of Columbia 20010, USA
| | - Manabu Natsumeda
- Department of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Jeffrey A Rubens
- Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Louis Rodgers
- National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
| | - Madhuri Kambhampati
- Research Center for Genetic Medicine, Children's National Health System, Washington, District of Columbia 20010, USA
| | - Isabella C Taylor
- Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Harpreet Kaur
- Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Laura Asnaghi
- Department of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Charles G Eberhart
- Department of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
| | - Katherine E Warren
- National Cancer Institute, National Institute of Health, Bethesda, MD 20892, USA
| | - Javad Nazarian
- Research Center for Genetic Medicine, Children's National Health System, Washington, District of Columbia 20010, USA; Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia 20052, USA
| | - Eric H Raabe
- Department of Pathology, Division of Neuropathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
| |
Collapse
|
43
|
Stampar M, Saratsis A, Brown K, Yadavilli S, Raabe E, Warren K, Kambhampati M, Giri M, Gupta N, Packer R, Nazarian J. HG-61MOLECULAR CHARACTERIZATION OF IN VIVOAND IN VITROMODELS OF DIPG. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now073.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Wells E, Kambhampati M, Damsker JM, Dressman-Gordish H, Yadavilli S, Becher OJ, Gittens J, Stampar M, Packer RJ, Nazarian J. HG-63NOVEL DISSOCIATIVE STEROIDS FOR TREATMENT OF EDEMA IN CHILDHOOD INTRACRANIAL BRAIN TUMORS. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now073.59] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
45
|
Gittens J, Yadavilli S, Kambhampati M, Damsker J, Becher OJ, Gupta N, Packer RJ, Nazarian J. HG-24GLUCOCORTICOID-MEDIATED EPIGENOMIC REVERSAL IN DIFFUSE INTRINSIC PONTINE GLIOMAS. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now073.21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Kambhampati M, Gittens J, Yadavilli S, Pai SB, McNeeley KM, Becher OJ, Packer RJ, Bellamkonda R, Fernandes R, Nazarian J. HG-64DEVELOPMENT OF IN VIVO DRUG AND GENE DELIVERY SYSTEMS TO BRAIN TUMOR USING LIPOSOMAL NANOCARRIERS. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now073.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Kambhampati M, Gittens J, Ho CY, Yadavilli S, Panditharatna E, Stampar M, Kilburn L, Hwang EI, Rood B, Packer RJ, Nazarian J. HG-62NEEDS AND MEANS OF POSTMORTEM BRAIN TUMOR DONATION AND COORDINATION: ONE CENTER'S EXPERIENCE. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now073.58] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
48
|
Yadavilli S, Yang X, Kilburn L, Magge S, Kambhampati M, Waanders A, Han H, Mueller S, Resnick A, Packer R, Nazarian J. HG-74DEVELOPMENT OF ROBUST IN VITRO AND IN VIVO PRE-CLINICAL MODELS FOR DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now073.70] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
49
|
Moser H, Kambhampati M, Gittens J, Ho CY, Yadavilli S, Panditharatna E, Stampar M, Lee S, Lin M, Nanavaty A, Kilburn L, Hwang E, Rood B, Packer R, Nazarian J. HG-89DEVELOPMENT OF A CHILDHOOD CENTRAL NERVOUS SYSTEM BIOREPOSITORY. Neuro Oncol 2016. [DOI: 10.1093/neuonc/now073.85] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
50
|
Yadavilli S, Scafidi J, Becher OJ, Saratsis AM, Hiner RL, Kambhampati M, Mariarita S, MacDonald TJ, Codispoti KE, Magge SN, Jaiswal JK, Packer RJ, Nazarian J. The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma. Oncotarget 2016; 6:12141-55. [PMID: 25987129 PMCID: PMC4494928 DOI: 10.18632/oncotarget.3716] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 03/11/2015] [Indexed: 12/13/2022] Open
Abstract
Diffuse intrinsic pontine gliomas (DIPGs) have a dismal prognosis and are poorly understood brain cancers. Receptor tyrosine kinases stabilized by neuron-glial antigen 2 (NG2) protein are known to induce gliomagenesis. Here, we investigated NG2 expression in a cohort of DIPG specimens (n= 50). We demonstrate NG2 expression in the majority of DIPG specimens tested and determine that tumors harboring histone 3.3 mutation express the highest NG2 levels. We further demonstrate that microRNA 129-2 (miR129-2) is downregulated and hypermethylated in human DIPGs, resulting in the increased expression of NG2. Treatment with 5-Azacytidine, a methyltransferase inhibitor, results in NG2 downregulation in DIPG primary tumor cells in vitro. NG2 expression is altered (symmetric segregation) in mitotic human DIPG and mouse tumor cells. These mitotic cells co-express oligodendrocyte (Olig2) and astrocyte (glial fibrillary acidic protein, GFAP) markers, indicating lack of terminal differentiation. NG2 knockdown retards cellular migration in vitro, while NG2 expressing neurospheres are highly tumorigenic in vivo, resulting in rapid growth of pontine tumors. NG2 expression is targetable in vivo using miR129-2 indicating a potential avenue for therapeutic interventions. This data implicates NG2 as a molecule of interest in DIPGs especially those with H3.3 mutation.
Collapse
Affiliation(s)
- Sridevi Yadavilli
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA
| | - Joseph Scafidi
- Department of Neurology and Center for Neuroscience Research, Children's National Health System, Washington, DC, USA
| | - Oren J Becher
- Department of Pediatrics and Pathology, Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA
| | - Amanda M Saratsis
- Division of Neurosurgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA
| | - Rebecca L Hiner
- Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, NY, USA
| | - Madhuri Kambhampati
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA
| | - Santi Mariarita
- Department of Pathology and Lab Medicine, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Tobey J MacDonald
- Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, USA
| | | | - Suresh N Magge
- Division of Neurosurgery, Children's National Health System, Washington, DC, USA
| | - Jyoti K Jaiswal
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA.,Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| | - Roger J Packer
- Brain Tumor Institute, Center for Neuroscience and Behavioral Medicine, Children's National Health System, Washington, DC, USA
| | - Javad Nazarian
- Research Center for Genetic Medicine, Children's National Health System, Washington, DC, USA.,Department of Integrative Systems Biology, George Washington University School of Medicine and Health Sciences, Washington, DC, USA
| |
Collapse
|